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Abstract Allostery is an inherent feature of proteins, but it remains challenging to reveal the
mechanisms by which allosteric signals propagate. A clearer understanding of this intrinsic circuitry
would afford new opportunities to modulate protein function. Here, we have identified allosteric
sites in protein tyrosine phosphatase 1B (PTP1B) by combining multiple-temperature X-ray
crystallography experiments and structure determination from hundreds of individual small-
molecule fragment soaks. New modeling approaches reveal ’hidden’ low-occupancy conformational
states for protein and ligands. Our results converge on allosteric sites that are conformationally
coupled to the active-site WPD loop and are hotspots for fragment binding. Targeting one of these
sites with covalently tethered molecules or mutations allosterically inhibits enzyme activity. Overall,
this work demonstrates how the ensemble nature of macromolecular structure, revealed here by
multitemperature crystallography, can elucidate allosteric mechanisms and open new doors for
long-range control of protein function.
DOI: https://doi.org/10.7554/eLife.36307.001
Introduction
Proteins are collections of atoms that are mechanically coupled to one another, which gives rise to
coordinated motions within the constraints of the folded structure. These motions are critical for
many processes in molecular biology, including small-molecule and protein:protein binding interac-
tions, catalytic cycles in enzymes, and allosteric communication between active sites and distal regu-
latory sites. Allostery in particular is now recognized to occur not only in classical oligomeric proteins
like hemoglobin but also in monomers – and indeed may be inherent to nearly all protein structures
(Motlagh et al., 2014; Gunasekaran et al., 2004). However, we do not yet understand at a funda-
mental level how mechanically coupled atoms underlie communication through protein structures,
which prevents us from mapping their intrinsic allosteric ‘circuitry’. Moreover, because protein
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surfaces are large and intermolecular interactions are complex, it is difficult to predict which surface
sites can bind an effector (such as a small molecule) that will allosterically communicate with the
active site. These gaps severely limit our ability to elucidate natural allosteric regulatory mechanisms
in biology, and to exploit allosteric circuitry in proteins for therapeutic intervention with perturba-
tions such as small molecules.
One system that would benefit immensely from an improved mechanistic understanding of allo-
stery is the archetypal protein tyrosine phosphatase, PTP1B (also known as PTPN1). PTP1B is highly
validated as a therapeutic target for diabetes (Elchebly et al., 1999) and cancer (Krishnan et al.,
2014) and has also been linked to Rett syndrome (Krishnan et al., 2015). Extensive efforts have
been made to develop active-site inhibitors for PTP1B. Unfortunately, active-site inhibitors in general
often bind non-specifically to homologous proteins, leading to off-target cellular effects
(DeDecker, 2000). Moreover, the active sites of many enzymes, including phosphatases, are highly
polar, and the polar inhibitors which bind to them often suffer from poor bioavailability (Hardy and
Wells, 2004; Zhang, 2001). Attempts have been made to circumvent these limitations and selec-
tively target the active site of PTP1B – for example, by linking non-hydrolyzable phosphotyrosine
(pTyr) analogs that bind the active site with small-molecule fragments that bind in nearby, less con-
served sites (Zhang, 2017). Nevertheless, no active-site inhibitors for PTP1B have reached clinical
use, leading some to label PTP1B ‘undruggable’.
By contrast, an allosteric inhibitor that binds to a less-conserved and less-polar surface site could
bypass the limitations of active-site inhibitors. Two classes of compounds have been identified that
allosterically inhibit PTP1B, although each has limitations. The first class of compounds are based on
a benzbromarone (BB) scaffold and inhibit allosterically by binding to the space normally occupied
by the regulatory C-terminal a7 helix (Wiesmann et al., 2004). Recent work combining mutagenesis,
X-ray crystallography, NMR spectroscopy, and molecular dynamics simulations revealed how rota-
tions of the a3 helix and a discrete switch of the catalytic WPD loop are impacted by these BB allo-
steric inhibitors (Choy et al., 2017). Unfortunately, the BB molecules were not successfully translated
to the clinic. The second class are natural products, including a molecule called MSI-1436, that bind
to multiple sites that primarily involve the disordered C-terminus (Krishnan et al., 2014). However,
the binding poses were not structurally resolved, limiting our ability to understand the molecules’
allosteric mechanism and rationally improve their potency. For example, a variant of MSI-1436 had
eLife digest Proteins perform many important jobs in each of the cells in our bodies, such as
transporting other molecules and helping chemical reactions to occur. The part of the protein
directly involved in these tasks is called the active site. Other areas of the protein can communicate
with the active site to switch the protein on or off. This method of control is known as allostery.
Switching proteins on and off could help us to develop treatments for certain diseases. For
example, a protein called PTP1B reduces how well cells can respond to insulin. Switching this
protein off could therefore help to treat diabetes. However, much like it’s hard to guess how a light
switch is wired to a light bulb without seeing behind the walls, it is hard to predict which remote
areas of a protein are ‘wired’ to the active site.
Keedy, Hill et al. have now used two complementary methods to examine the structure of PTP1B
and find new allosteric sites. The first method captured a series of X-ray images from crystallized
molecules of the protein held at different temperatures. This revealed areas of PTP1B that can move
like windshield wipers to communicate with each other. The second method soaked PTP1B crystals
in trays with hundreds of drug-sized molecules and assessed which sites on the protein the
molecules bound to. The molecules generally bound to just a few sites of the protein. Further tests
on one of these sites showed that it can communicate with the active site to turn the protein on or
off.
Further work will be needed to develop drugs that could treat diabetes by binding to the newly
identified allosteric sites in PTP1B. More generally, the methods developed by Keedy, Hill et al.
could be used to study allostery in other important proteins.
DOI: https://doi.org/10.7554/eLife.36307.002
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improved inhibition but a different response to mutations at the putative binding sites, suggesting
an unknown change in mechanism (Krishnan et al., 2018). MSI-1436 passed Phase I clinical trials but
was not advanced to Phase II (Ghattas et al., 2016). A new approach to revealing the intrinsic allo-
steric circuitry of proteins would reveal different opportunities to develop allosteric inhibitors for
PTP1B that could potentially overcome the limitations of these existing molecules. Such an approach
would additionally set the stage for efforts to dissect allosteric regulatory strategies in other biologi-
cally important phospho-signaling proteins.
Here, we have addressed the challenge of discovering unique opportunities for allosteric inhibi-
tion of PTP1B by taking advantage of two new techniques in X-ray crystallography that reveal minor
conformational states of protein and ligands. First, multitemperature crystallography (Keedy et al.,
2015b) can reveal previously hidden alternative conformations that enable biological functions.
Here, we use this approach in PTP1B to reveal alternative conformations that are coupled to each
other, forming an allosteric network. Our findings provide support for the previously hypothesized
allosteric network in PTP1B that responds to BB inhibitors (Choy et al., 2017). Moreover, they reveal
extensions of this network, including additional allosteric binding sites that are distinct from the BB
site (Figure 1). Similar regions of PTP1B have been implicated as allosteric sites based on mutagene-
sis coupled with traditional cryogenic X-ray crystallography, molecular dynamics simulations, and
NMR spectroscopy (Choy et al., 2017; Cui et al., 2017); here, we complement those studies by
using multitemperature crystallography to reveal in atomic detail the conformational heterogeneity
that allosterically links these sites to the active site. Second, high-throughput small-molecule frag-
ment soaking and structure determination (Collins et al., 2017) has enabled new algorithms for
revealing low-occupancy ligands (Pearce et al., 2017). We use this approach to comprehensively
canvas the PTP1B surface with 1627 small-molecule fragments, 110 of which were structurally
resolved in complex with PTP1B. The fragments cluster into 11 fragment-binding hotspots outside
of the active site. To prioritize putative allosteric sites rather than benign binding sites, we focused
on the subset of fragment-binding sites that were also conformationally coupled to the active site
based on multitemperature crystallography of apo PTP1B. Strikingly, the sites chosen in this way
Figure 1. Schematic of key structural components in PTP1B. (A) The ‘front side’ of PTP1B features the active site covered by the dynamic catalytic WPD
loop, as well as several other structural elements relevant to substrate recognition and binding. The a6 helix next to the WPD loop leads into the a7
helix and disordered C-terminus, which are positioned near loop 11 (partially occluded in this view). (B) On the ‘back side’ of PTP1B, with the view
rotated by roughly 180˚, the a7 helix and disordered C-terminus sit atop the a3 helix, the a6 helix, and the edge of the central b sheet including loop
11. The pocket between the a3 helix and the b sheet includes several sidechains which interact with each other, leading to the ‘197 site’ (green).
Elsewhere on the back side, a sidechain in loop 16 interacts with the a6-a7 connection to form the ‘loop 16 site’ or ‘L16 site’ (blue). These two allosteric
sites are distinct from the previously established ‘BB site’ (orange) (Wiesmann et al., 2004), which is underneath the a7 helix that is displaced by BB
allosteric inhibitor binding. As PTP1B transitions between its global states, many of the key structural components illustrated here undergo coordinated
conformational changes, which together define the protein’s intrinsic allosteric circuitry.
DOI: https://doi.org/10.7554/eLife.36307.003
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bound more fragments than did any other sites – suggesting that conformational heterogeneity may
be important for both allostery and ligand binding. Our work builds on previous studies of these
sites in PTP1B (Choy et al., 2017; Cui et al., 2017), which did not report chemical matter that binds
to them. Finally, we use covalently tethered small molecules (Erlanson et al., 2004) at one of these
sites to confirm that it is functionally linked to enzyme activity, thereby supporting our predictions
from multitemperature crystallography of the apo protein.
Overall, by highlighting promising allosteric sites and ligands that bind to them, our work may aid
future development of potent non-covalent small-molecule allosteric inhibitors for PTP1B. More
broadly, we illustrate a generalizable approach to characterizing and exploiting coupled conforma-
tional heterogeneity to enable long-range control of protein function.
Results
Identifying allosterically coupled residues with multitemperature
crystallography
To identify allosteric sites in PTP1B that can communicate with the active site, we searched for
regions of the protein whose conformational heterogeneity is coupled to that of the active site. We
began by examining the conformational heterogeneity of the active-site WPD loop. Transition of this
loop from the open to the closed state is rate-limiting for catalysis (Whittier et al., 2013). In the
only available apo crystal structure of PTP1B in which the WPD loop is free from crystal-lattice con-
tacts (PDB ID 1sug) (Pedersen et al., 2004), the loop is modeled in the closed state. However, low-
contour electron density can reveal hidden alternative conformations in protein crystal structures
(Lang et al., 2010; Fraser et al., 2011). We therefore investigated the electron density near the
WPD loop in the apo structure more closely (Figure 2B).
Surprisingly, upon closer inspection, the electron density strongly suggests a significant popula-
tion for the open state as well (Figure 2C, left). Our re-refined model with both open and closed
states as alternative conformations visually accounts for the electron density around this loop much
better than the original model (Figure 2C, left). By contrast, when we re-refined 36 other available
crystal structures of PTP1B complexed with active-site inhibitors using both open and closed loop
states as putative alternative conformations, Fo-Fc difference electron density and the bimodal dis-
tribution of refined occupancies indicated the single-state models were a better fit (Figure 2—figure
supplement 1). These results suggest that, even in the crystal, apo PTP1B samples both WPD loop
states and that active-site inhibitors then lock the loop either fully open or fully closed.
To better characterize the conformational heterogeneity of the WPD loop in apo PTP1B, we col-
lected X-ray datasets at several elevated temperatures including 180 K, 240 K, and 278 K (‘room
temperature’) in addition to the 100 K (‘cryogenic’) model from the PDB, all at better than 2 A˚ reso-
lution (Table 1). Each complete dataset was obtained from a single crystal, and crystallographic sta-
tistics indicated that radiation damage was not a concern even at the elevated temperatures
(Diederichs, 2006) (Figure 2—figure supplement 3). We built an initial multiconformer model for
each temperature using the automated algorithm qFit (Keedy et al., 2015a). These models are par-
simonious in that each atom has alternative positions only if justified by the experimental data, and a
single position otherwise. Such models are equally good and usually better explanations of the
experimental X-ray data (Keedy et al., 2015a; van den Bedem et al., 2009), and have been used to
understand many biologically relevant phenomena at protein:water interfaces (Keedy et al., 2014),
dynamic enzyme active sites (Keedy et al., 2015b; Fraser et al., 2009), and allosteric networks per-
turbed by mutations (van den Bedem et al., 2013). We then manually refined alternative conforma-
tions for protein, buffer components, and solvent. In particular, we took advantage of the wealth of
available structures of PTP1B in the PDB (Berman et al., 2000) to sample coordinates for putative
alternative conformations; in many cases, these conformations explained missing regions with posi-
tive Fo-Fc electron density that would have otherwise been difficult to model. Removing the alterna-
tive conformations and re-refining the resulting single-conformer models, either with or without
automated solvent placement, yields deteriorated statistics (Table 1— source data 1), which con-
firms that the multiconformer models are appropriate explanations of the experimental data at each
temperature.
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The WPD loop adopts both the open and closed conformations across this range (Figure 2C) and
the population of the open vs. closed states was sensitive to temperature (Figure 2D). The loop is
approximately 67% closed at 100 K, but 65% open at 278 K. These occupancies evolve non-linearly
(Keedy et al., 2015b) at intermediate temperatures.
Overall, we also observed temperature-dependent conformational heterogeneity for several
other regions of PTP1B, including the previously characterized BB allosteric site, plus additional sites
we refer to as the ‘197 site’ and the ‘loop 16 (L16) site’. These regions are all contiguous in the struc-
ture (Figure 2E), suggesting that they together constitute an expanded collective allosteric network
in PTP1B that is coupled to the WPD loop. The manner in which they are connected is described in
detail in the following sections.
Figure 2. The conformational ensemble of the active-site WPD loop and allosterically coupled regions. (A) The active-site WPD loop in PTP1B adopts
either a closed conformation (example from PDB ID 1sug) or an open conformation (example from PDB ID 1t49). View from the ‘front side’ of PTP1B. (B)
In the previously published apo structure of PTP1B, solved at 100 K (PDB ID 1sug), 0.8 s 2Fo-Fc electron density (cyan) supports the modeled closed
conformation, but substantial electron density remains unexplained (arrow). (C) Adding the open conformation of the WPD loop as a secondary
conformation at partial occupancy accounts for this electron density. In structures solved at different elevated temperatures, electron density for the
open conformation becomes more prominent as its occupancy (labeled) relative to the closed conformation increases. (D) The occupancy of the open
conformation increases non-linearly with temperature. (E) Overall roadmap of allostery on the ‘back side’ of PTP1B, with the allosteric 197 site and loop
16 (L16) site highlighted in the context of the larger allosteric network including the previously established BB site, a7 helix, and WPD loop. Sidechains
are shown in stick representation for several key residues in the WPD loop and allosteric regions. For those residues with alternative conformations at
278 K, both open-state (darker hues) and closed-state (lighter hues) conformations are shown. The viewing orientation in (A–C) is as in Figure 1A (‘front
side’ of PTP1B), except zoomed in on the active site (labeled in Figure 1A). The viewing orientation in (E) is as in Figure 1B (‘back side’ of PTP1B).
DOI: https://doi.org/10.7554/eLife.36307.004
The following video and figure supplements are available for figure 2:
Figure supplement 1. The WPD loop adopts multiple conformations only in the absence of inhibitors.
DOI: https://doi.org/10.7554/eLife.36307.005
Figure supplement 2. Mutually exclusive partial-occupancy protein and solvent atoms complicate model building.
DOI: https://doi.org/10.7554/eLife.36307.006
Figure supplement 3. Radiation damage is minimal across all datasets.
DOI: https://doi.org/10.7554/eLife.36307.007
Figure 2—video 1. Movie version with five scenes: Figure 2B then Figure 2C.
DOI: https://doi.org/10.7554/eLife.36307.008
Figure 2—video 2. Movie version of Figure 2E.
DOI: https://doi.org/10.7554/eLife.36307.009
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Table 1. Crystallographic statistics for multitemperature and mutant X-ray datasets.
Overall statistics given first (statistics for highest-resolution bin in parentheses). For WT apo, 100 K: statistics are taken from our remod-
eled structure where appropriate, or from the original PDB ID 1sug when possible otherwise, or given as ‘—” where unavailable.
WT apo, 100 K WT* apo, 180 K
WT* apo,
240 K WT* apo, 278 K
WT* with BB3,
278 K
K197C apo, 100
K
K197C tethered
to 2, 100 K
PDB ID 6B90 6B8E 6B8T 6B8X 6B8Z 6BAI 6B95
Number of crystals
used
1 1 1 1 1 1 1
Wavelength (A˚) 0.8110 1.115869 1.115869 0.9795 1.11583 1.11583 1.11583
Resolution range
(A˚)
33.60–1.95 (2.02–
1.95)
19.18–1.82 (1.89–
1.82)
62.54–1.85
(1.92–1.85)
31.31–1.74 (1.80–
1.74)
43.88–1.8 (1.86–
1.8)
75.57–1.95 (2.02–
1.95)
43.98–1.95 (2.02–
1.95)
Space group P 31 2 1 P 31 2 1 P 31 2 1 P 31 2 1 P 31 2 1 P 31 2 1 P 31 2 1
Unit cell
(A˚, ˚)
88.12 88.12 103.90
90 90 120
88.57 88.57 104.32
90 90 120
89.44 89.44
106.00
90 90 120
89.52 89.52 106.25
90 90 120
89.65 89.65 106.39
90 90 120
87.27 87.27 104.10
90 90 120
87.96 87.96 104.63
90 90 120
Total reflections — 339461 (33574) 256701
(25484)
299041 (30678) 771858 (76158) 653798 (63759) 170094 (16845)
Unique reflections 34486 (3371) 42866 (4223) 42343 (4156) 50486 (4960) 46311 (4561) 33409 (3296) 34596 (3387)
Multiplicity 7.4 (—) 7.9 (7.9) 6.1 (6.1) 5.9 (6.2) 16.7 (16.7) 19.6 (19.3) 4.9 (5.0)
Completeness (%) 99.9 (100.0) 99.9 (100.0) 100.0 (100.0) 99.0 (98.3) 100.0 (100.0) 98.06 (98.51) 99.81 (99.88)
Mean I/sigma(I) 26.4
(4.4)
21.40 (1.46) 15.89 (1.46) 17.15 (1.49) 11.69 (0.75) 25.06 (0.94) 12.04 (0.81)
Wilson B (A˚2) 24.12 23.69 28.48 19.48 34.96 46.3 38.82
Rmerge 0.073 (0.515) 0.089 (1.483) 0.079 (1.215) 0.098 (1.209) 0.148 (2.664) 0.076 (3.056) 0.088 (1.852)
Rmeas — 0.096 (1.585) 0.086 (1.329) 0.108 (1.318) 0.153 (2.748) 0.078 (3.138) 0.098 (2.071)
Rpim — 0.034 (0.556) 0.035 (0.535) 0.044 (0.520) 0.038 (0.672) 0.018 (0.705) 0.044 (0.916)
CC1/2 — 0.999 (0.520) 0.999 (0.560) 0.999 (0.496) 0.997 (0.366) 1.000 (0.438) 0.999 (0.292)
CC* — 1.000 (0.827) 1.000 (0.847) 1.000 (0.814) 0.999 (0.732) 1.000 (0.781) 1.000 (0.672)
Reflections used in
refinement
34486 (3371) 42862 (4223) 42343 (4156) 50486 (4959) 46309 (4561) 33302 (3296) 34576 (3386)
Reflections used for
Rfree
1356 (128) 1689 (165) 1669 (163) 1993 (196) 1820
(176)
1310
(135)
1362
(135)
Rwork 0.1580 (0.1881) 0.1708 (0.2781) 0.1674
(0.2760)
0.1752 (0.3511) 0.1675 (0.3116) 0.2061 (0.3365) 0.1858 (0.3295)
Rfree 0.1926 (0.2090) 0.1997 (0.2911) 0.2123
(0.2869)
0.2059 (0.3888) 0.1978 (0.3017) 0.2569 (0.3292) 0.2307 (0.3686)
CCwork — 0.963 (0.753) 0.958 (0.789) 0.964 (0.673) 0.964 (0.709) 0.934 (0.618) 0.957 (0.574)
CCfree — 0.948 (0.744) 0.908 (0.677) 0.948 (0.739) 0.961 (0.757) 0.994 (0.484) 0.938 (0.294)
Non-H atoms 2997 3021 3149 3260 2709 2502 2541
Macromolecule
atoms
2657 2687 2875 3011 2460 2377 2370
Ligand atoms 46 40 34 24 82 16 36
Solvent atoms 294 294 240 225 167 109 135
Protein residues 298 298 299 298 289 282 285
RMS bonds (A˚) 0.010 0.011 0.011 0.012 0.011 0.015 0.013
RMS angles (˚) 1.01 1.02 1.10 1.08 1.14 1.30 1.15
Ramachandran
favored (%)
97.64 97.64 97.98 95.95 97.19 95.00 95.76
Ramachandran
allowed (%)
2.03 2.03 1.68 3.72 2.11 4.64 2.83
Ramachandran
outliers (%)
0.34 0.34 0.34 0.34 0.70 0.36 1.41
Table 1 continued on next page
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Multitemperature crystallography of the BB allosteric site
To connect these multitemperature structures to known allosteric regulatory mechanisms, we first
turned to a benzbromarone derivative compound (here referred to as BB2) that binds to an allosteric
site >12 A˚ away from the active site and inhibits enzyme activity (Wiesmann et al., 2004). The
authors of the study reporting BB2 described a series of induced conformational changes that
begins with BB2 directly displacing Trp291 to disorder the entire C-terminal a7 helix, and ends with
Phe191 c2 dihedral-angle rotations clashing with the WPD loop anchor residue Trp179 to stabilize
the open state. We tested the hypothesis that these allosterically inhibited conformations pre-exist
in apo PTP1B by examining these regions in our multitemperature apo crystal structures. Indeed, in
apo PTP1B the a7 helix is more ordered at lower temperatures but more disordered at higher tem-
peratures (Figure 3A). Also, Trp179 and Phe191 adopt dual conformations at higher temperatures
(Figure 3B) that coincide well with the apo and allosterically inhibited conformations (Figure 3C).
We also see alternative conformations at high temperatures for several residues within and directly
flanking the WPD loop (Arg221, Pro185, Trp179, Phe269) which have been implicated as being
important for a CH/p switch during WPD loop opening/closing (Choy et al., 2017) (Figure 3—figure
supplement 1). Multiple conformations for Leu192 were more difficult to detect at higher tempera-
tures in apo PTP1B. This is likely because Leu192 shifts more subtly between the 100 K apo and allo-
sterically inhibited conformations, which is also consistent with a recent report that Leu192 is a
relatively static inter-helical ‘wedge’ (Choy et al., 2017). Taken together, these results suggest that
BB2 stabilizes a subset of pre-existing conformations in apo PTP1B.
We additionally solved a high-resolution (1.80 A˚, Table 1) structure of PTP1B in complex with
BB3 (which differs from BB2 only by an extra terminal aminothiazole group) at 273 K and found it to
be very similar to the 100 K structures with BB3 (PDB ID 1t4j) and with BB2 (PDB ID 1t49) despite
the difference in temperature (Figure 3—figure supplement 2). However, two interesting features
are evident at 273 K. First, at 273 K but not at 100 K, modeling BB3 with a single conformer leads to
Fo-Fc difference electron density peaks at both ends of the molecule (Figure 3—figure supplement
3A). To account for these peaks in the map, it is necessary to add a second alternative conformer to
the model, which includes a translation at one end and dihedral-angle changes at the other end
Table 1 continued
WT apo, 100 K WT* apo, 180 K
WT* apo,
240 K WT* apo, 278 K
WT* with BB3,
278 K
K197C apo, 100
K
K197C tethered
to 2, 100 K
Rotamer outliers
(%)
1.35 2.67 1.87 2.38 2.19 6.44 4.91
Clashscore 2.79 3.31 3.62 2.98 2.79 6.06 3.36
MolProbity score 1.24 1.52 1.36 1.65 1.47 2.29 1.95
Average B (A˚2) 29.35 30.22 36.50 28.06 43.58 55.81 49.66
Average B,
macromolecule (A˚2)
28.14 29.11 35.51 27.01 43.30 56.02 49.53
Average B, ligands
(A˚2)
47.43 48.08 60.29 67.33 41.13 45.41 53.91
Average B, solvent
(A˚2)
37.46 37.90 44.96 38.01 48.96 52.76 50.82
DOI: https://doi.org/10.7554/eLife.36307.010
The following source data is available for Table 1:
Source data 1. Multiconformer models best explain PTP1B X-ray data across temperatures.
R-factors are reported for the deposited multiconformer models for multitemperature datasets in Table 1 vs. single-conformer models derived by
removing alternative conformations and re-refining with Phenix either with default parameters (‘without solvent picking’) or with automated water place-
ment turned on by adding the flag ‘ordered_solvent = True’ (‘with solvent picking’) for 12 macro-cycles. For the new single-conformer models, R-factors
are given both for state A with state B’s alternative conformations removed, and for state B with state A’s alternative conformations removed, to confirm
that either option for a single-conformer model is worse than a multiconformer model. Overall, regardless of the choice of solvent parameters, at each
temperature the multiconformer model has lower (better) Rwork and Rfree.
DOI: https://doi.org/10.7554/eLife.36307.011
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Figure 3. Multitemperature crystallography of apo PTP1B recapitulates an allosteric mechanism. (A) In apo PTP1B,
the occupancy of the a7 helix decreases (i.e. the helix becomes more disordered) with temperature. The helix was
modeled with one conformation and its occupancy was refined; the remaining occupancy corresponds to the
disordered state of the helix. (B) Several residues that allosterically link a7 and the active-site WPD loop also
undergo shifts with temperature. (C) These additional conformations match the state trapped by the allosteric
inhibitor BB2 (PDB 1t49) (Wiesmann et al., 2004) which binds >12 A˚ away from the active site. The viewing
orientation in (B–C) is as in Figure 1A (‘front side’ of PTP1B), except slightly zoomed in.
DOI: https://doi.org/10.7554/eLife.36307.012
The following figure supplements are available for figure 3:
Figure supplement 1. Alternative conformations in apo PTP1B recapitulate a reported conformational switching
mechanism in the active site during WPD loop closing.
DOI: https://doi.org/10.7554/eLife.36307.013
Figure supplement 2. Allosteric inhibitor binding quenches conformational heterogeneity regardless of
temperature.
DOI: https://doi.org/10.7554/eLife.36307.014
Figure supplement 3. Allosteric-inhibitor-bound PTP1B has some low-occupancy conformations only at 273 K.
DOI: https://doi.org/10.7554/eLife.36307.015
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(Figure 3—figure supplement 3B). Chemical changes to BB3 designed to eliminate this remaining
heterogeneity could potentially improve affinity and inhibition.
Second, at 273 K, we observe significant electron density just above BB3 (Figure 3—figure sup-
plement 3C). Modeling a reordered, non-helical conformation of a7 explains this density well, and
places Trp291 in good position for aromatic stacking interactions with BB3 and other interactions
with nearby sidechains on the a3 helix (Figure 3—figure supplement 3D). Trp291 is displaced by
BB3 or BB2 binding in a striking example of molecular mimicry (Wiesmann et al., 2004) (Figure 3C).
Our 273 K data suggest that a subsequent reordering of the a7 polypeptide occurs, which may con-
tribute to the affinity of BB3 for PTP1B. In contrast to our 273 K data, electron density in this region
is weak in the 100 K structures with BB3 and BB2. However, in the 100 K structure with BB1, a differ-
ent derivative of the BB scaffold, a7 also reorders – but adopts a significantly different conformation
than we observe at 273 K with BB3 (Figure 3—figure supplement 3E,G). Together, these results
suggest that in addition to being a major allosteric hub when ordered (Choy et al., 2017), a7 is also
quite malleable when disordered, and may interact in diverse ways with bound ligands – behavior
which is similar to the mechanism proposed for inhibitors that bind via the disordered C-terminus
beyond a7 (Krishnan et al., 2014).
Multitemperature crystallography of the allosteric loop 16 site
We also observed temperature-dependent ordering in a loop (loop 16, L16; residues 237–243) that
sits underneath the a6-a7 junction just beyond the BB binding site. By contrast to lower temperature
(Figure 4A), the electron density for L16 at higher temperature (Figure 4B) clearly reveals an alterna-
tive conformation with its backbone shifted by >5 A˚ from the primary conformation (Figure 4D).
Modeling this alternative loop conformation back into the lower-temperature models and refining its
occupancy reveals a temperature dependence (Figure 4E, Figure 4—figure supplement 1) that is
qualitatively similar to the temperature dependences of the WPD loop. Remarkably, this L16 alterna-
tive conformation sampled by apo PTP1B matches the L16 conformation when PTP1B is allosterically
inhibited by BB2 (Figure 4C). This rearrangement provides further evidence that BB2 selects pre-
existing, globally dispersed conformations rather than inducing new ones.
The L16 site is seemingly coupled to the a6 helix: Lys239 from L16 H-bonds with Ile281 from a6
in the global closed state, but not in the global open state in which L16 adopts its alternative confor-
mation. Because a6 is directly coupled to the a7 order-disorder transition, we therefore propose
that the L16 site is a component of the collective allosteric network in PTP1B.
The L16 site was not identified as part of the allosteric network in PTP1B based on a study using
mutagenesis, NMR, and MD (Choy et al., 2017). However, in a more recent study, several residues
lining what we call the L16 site (including Met3, Lys237, and Ser242) were included in a region called
‘Cluster II’, which was suggested to be a previously unidentified allosteric site based on reciprocal
NMR chemical shift perturbations upon mutation of this site or the WPD loop (Cui et al., 2017). Our
work here using multitemperature crystallography complements these findings by independently
identifying this allosteric site using a new methodology, and by revealing in atomic detail how multi-
ple conformational states at the L16 site may aid communication with the active site. Interestingly, a
separate approach combining molecular dynamics and machine learning also recently pointed to
this area as a potential ‘cryptic’ binding site (Cimermancic et al., 2016a). Therefore, the L16 site
may be not only energetically coupled to the active site, but also capable of forming an under-
appreciated small-molecule binding pocket via the conformational heterogeneity we observe.
Multitemperature crystallography of the allosteric 197 site
In addition to the temperature-dependent conformational heterogeneity observed at the BB site
and L16 site, we observed residues with temperature-sensitive conformational heterogeneity in the
‘197 site’ (Figure 5). Moreover, the alternative conformations of several residues in this region have
a pattern of steric incompatibility with multiple states of the WPD loop and a7 helix, suggesting that
the 197 site may be mechanistically linked to the active site in a similar way as the BB binding site.
A major link between the WPD loop and the 197 site is Tyr152. When the WPD loop is closed
and the a7 helix is ordered, Tyr152 adopts a ‘down rotamer’ (Figure 5—figure supplement 1, red).
By contrast, when the WPD loop is open and the a7 helix is disordered, the 278 K electron density
suggests that Tyr152 adopts an ‘up rotamer’ (Figure 5—figure supplement 1C, orange). However,
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difference electron density peaks remain (Figure 5—figure supplement 1C) that indicate the pres-
ence of the down rotamer as an alternative conformation. Consistent with this interpretation, model-
ing just the additional down rotamer is insufficient to explain the density (Figure 5—figure
supplement 1D). These two rotamers are accommodated in the WPD-loop-open state by a shift of
the L11 backbone (Figure 5—figure supplement 1). The down rotamer is sterically incompatible
with phosphorylation of Tyr152, which occurs in vivo (Bandyopadhyay et al., 1997; Rhee et al.,
2001), suggesting that the up rotamer may have additional regulatory roles. Tyr152 in the L11 back-
bone conformation with just the down rotamer (red in Figure 5—figure supplement 1) is sterically
incompatible with the open WPD loop conformation (Figure 5—figure supplement 1E). Similarly,
the Tyr152 up rotamer is sterically incompatible with the ordered a7 conformation (Figure 5—figure
supplement 1E). In turn, a7 is conformationally synchronized with the WPD loop (Figure 3A and
Figure 2D) and is a key hub connecting loop 11 and the WPD loop (Choy et al., 2017). These results
together suggest that the allosteric circuitry of PTP1B involving Tyr152 is complex and multibody.
Tyr152 likely exemplifies a population shuffling mechanism whereby mixtures of microstates (rota-
meric state of Tyr152) exchange on a fast timescale as the protein transitions between macrostates
(WPD loop state, a7 ordering, and L11 backbone shifting) on a slower timescale (Smith et al.,
2015). Our findings thus shed additional light on the mechanism by which loop 11 allosterically
Figure 4. Both an allosteric inhibitor and high temperature favor an alternative conformation for an a7-coupled loop 16. (A) At low temperature, loop
16 (residues 237–243, bottom right) is single-conformer, as evidenced by 2Fo-Fc electron density contoured at 1.0 s (cyan volume) and at 1.0 s (blue
mesh). (B) At high temperature, when the protein is modeled as single-conformer, the electron density suggests the existence of an alternative
conformation. (C) The structure with BB2 bound (>12 A˚ away) (PDB ID 1t49) perfectly explains the mysterious electron density. (D) The final 278 K dual-
conformation model is a good explanation of the data. (E) The refined occupancy of the alternative conformation (state ‘B’) in apo PTP1B increases
continuously but non-linearly with temperature. The viewing orientation in (A–D) is as in Figure 1B (‘back side’ of PTP1B), except zoomed in on the
loop 16 site (labeled in Figure 1B).
DOI: https://doi.org/10.7554/eLife.36307.016
The following figure supplement is available for figure 4:
Figure supplement 1. The conformational distribution of the a7-coupled loop 16 titrates with temperature.
DOI: https://doi.org/10.7554/eLife.36307.017
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Figure 5. Coupled conformational heterogeneity leads to the allosteric 197 site. (A) Several residues distinct from both the active site and a previously
characterized allosteric network each have minor alternative conformations that become more populated with temperature. This is quantified by the
sum of 2Fo-Fc electron density values for the centers of atoms that are unique to the minor state (defined as being at least 1.0 A˚ away from any atoms
in the major state), normalized across temperatures from 0 to 1 for each residue. (B) These residues colocalize to a region of the protein surrounded by
loop 11 (top-left), the quasi-ordered a7 helix (top-right), and the a3 helix (right), including the eponymous K197. 2Fo-Fc electron density contoured at
0.6 s (cyan volume) and at 0.8 s (blue mesh) justify multiple conformations for these residues in our 278 K apo model, as quantified in (A). The
alternative conformations of these residues appear to interact with one another and thus may be allosterically coupled. Ordered crystallization mother
liquor or cryoprotectant molecules (glycerols in pink, from the PDB and our structures, or MPD molecules in green, from the PDB) can be present at the
terminus of this allosteric pathway, suggesting it may be amenable to binding other small molecules. The viewing orientation in B) is as in Figure 1B
(‘back side’ of PTP1B), except zoomed in on the 197 site (labeled in Figure 1B).
DOI: https://doi.org/10.7554/eLife.36307.018
The following video and figure supplements are available for figure 5:
Figure supplement 1. Alternative conformations in apo PTP1B recapitulate and expand upon reported coupling between loop 11 and a3.
DOI: https://doi.org/10.7554/eLife.36307.019
Figure supplement 2. The allosteric 197 site has local sequence differences in related PTPs.
DOI: https://doi.org/10.7554/eLife.36307.020
Figure supplement 3. Mutations along the 197 site’s allosteric pathway reduce enzyme activity.
DOI: https://doi.org/10.7554/eLife.36307.021
Figure supplement 4. Flexible aromatic residues complete an allosteric circuit.
DOI: https://doi.org/10.7554/eLife.36307.022
Figure 5—video 1. Movie version of Figure 5B.
DOI: https://doi.org/10.7554/eLife.36307.023
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communicates with the active site, thus complementing other recent studies using mutagenesis,
MD, and NMR to map allostery in PTP1B (Choy et al., 2017; Cui et al., 2017).
In our datasets at temperatures above 100 K, the electron density suggests a complex interplay
between alternative conformations for Asn193 on the a3 helix and Tyr152 on loop 11 (L11) (Fig-
ure 5—figure supplement 1). Asn193 is part of the a3 helix (residues 187–202), which immediately
follows the WPD loop in sequence. The N-terminal region of this helix (through Phe196) rotates by
2–20˚, resulting in shifts of 0.2–0.7 A˚ for some Ca atoms, based on 100 K crystal structures of apo
(WPD-open) vs. active-site-inhibitor-bound (WPD-closed) PTP1B (Choy et al., 2017). Similarly, the
multiconformer model for our 278 K apo dataset includes alternative backbone conformations for
the WPD loop and the beginning of a3, through Asn193 plus Phe196-Lys197 (this is a conservative
interpretation of which residues in the helix have alternative backbone conformations). Our results
suggest that a3 inherently shifts as the protein transitions betweens its global macrostates, even in
the apo state.
Strikingly, several residues propagating down L11 from Tyr152, and down a3 from Asn193, also
adopt multiple conformations at higher temperatures (Figure 5). These residues colocalize in a shal-
low pocket nestled between loop 11, the b4 and b5 strands, and the a3 and a7 helices. We refer to
this area here as the ‘197 site’ because the sidechain of Lys197 extends into the pocket. Our analysis
indicates a complex, interconnected network involving multiple aromatic stacking, hydrogen-bond-
ing, van der Waals, and electrostatic interactions. To complement this model-based assessment with
a map-based approach, for several residues in the pocket we quantified electron density as a func-
tion of temperature for atom positions that are unique to the minor conformation (i.e. do not overlap
with any atoms in the major conformation), reasoning that residues which respond to temperature
similarly may be conformationally coupled (Keedy et al., 2015b). The population of each minor con-
formation increases non-linearly with temperature (Figure 5A) in a similar fashion as the open state
of the WPD loop (Figure 2D) and the disordered state of the a7 helix (Figure 3A), in support of the
idea that these various regions of the protein are mutually conformationally coupled.
We next discuss several similarities and a few differences between what we refer to as the 197
site and similar regions implicated by other recent studies of allostery in PTP1B. First, in addition to
predicting the L16 site (see above), reciprocal chemical shift changes upon mutation suggested that
several residues at both ends of the 197 site (Tyr152, Tyr153, Lys150, Arg105) are part of a region
referred to as ‘Cluster I’ that is allosterically linked to the active site (Cui et al., 2017). However, that
study did not implicate additional key residues on the a3 helix, for example Asn193 and Lys197. Sec-
ond, mutagenesis, NMR, and cryogenic crystallography implicated several elements of our 197 site
as being part of the larger allosteric network in PTP1B: loop 11 (including Tyr152 and Tyr153), the
a3 helix (especially Asn193), and the a7 helix (Choy et al., 2017). Chemical-shift-restrained molecu-
lar dynamics simulations further suggested that Tyr152 on loop 11 and Asn193 on the a3 helix have
mutually coupled alternative conformations (Choy et al., 2017). However, here we highlight addi-
tional residues (e.g. Asp148 and Glu157 on the b strands on either end of loop 11) as being confor-
mationally coupled to each other and to the rest of the allosteric network and the active site, and
which may collectively form a binding pocket. Therefore, our work accomplishes two things with
regard to these existing studies. First, we add support to their findings by reaching similar conclu-
sions using orthogonal methods. Second, we complement the other studies by revealing additional
amino acid residues that may play roles in binding and allosteric communication at the 197 site.
We also emphasize that the 197 site is structurally distinct from the two allosteric sites that have
previously been targeted with small molecules to achieve inhibition (Krishnan et al., 2014;
Wiesmann et al., 2004), so any small molecules that bind to the 197 site would represent a distinct
strategy for inhibiting PTP1B. Surprisingly, in all of our multitemperature apo structures, ordered
glycerols are present not only in the active site as mentioned above but also in the 197 site (Fig-
ure 5—figure supplement 2), and MPD also binds here in another published structure (PDB ID
2cm2). These observations suggest that the 197 site may be bindable by other small molecules. We
therefore hypothesized that binding of a small molecule to the 197 site could propagate changes in
conformational heterogeneity to the WPD loop to interfere with catalysis.
To test whether more directed perturbations to the 197 site can allosterically modulate enzyme
function, we introduced ‘dynamically destructive’ mutations (Y152G, Y153A, K197A) that were pre-
dicted to preserve the protein’s general structure, yet interfere with the conformational heterogene-
ity along the putative allosteric pathway lining the 197 site by removing interactions between
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alternative conformations. For Y152 we chose a mutation to glycine instead of alanine to more fully
disengage residue 152 from the WPD loop, given that the Cb and Hb atoms of Y152 sterically
engage with the WPD loop (Figure 5—figure supplement 1E). All three mutations indeed reduce
catalytic efficiency, to varying extents: the mutation nearest to the WPD loop (Y152G) reduced kcat/
KM the most, and the mutation farthest from the WPD loop (K197A) reduced kcat/KM the least (Fig-
ure 5—figure supplement 3). Our results are generally in line with reported effects for the
Y152A + Y153A (‘YAYA’) double mutation (Choy et al., 2017) and for the Y153A single mutation
(Cui et al., 2017); small discrepancies may be due in part to differences in the length of the protein
construct being used. Overall, our results illustrate that local perturbations in the vicinity of the allo-
steric 197 site can impact catalysis.
Overall, we describe a large, collectively coupled allosteric network on one contiguous face of
the protein (Figure 2E). This network is interconnected not only on the surface, but also within the
hydrophobic core. For example, Tyr176 adopts alternative sidechain conformations at higher tem-
peratures that differ by a small rotation of the relatively non-rotameric c2 dihedral angle
(Lovell et al., 2000) (Figure 5—figure supplement 4). The two conformations of Tyr176 are struc-
turally compatible with different conformations of the surface-exposed Tyr152 (Choy et al., 2017;
Cui et al., 2017) in one direction, and of the buried Trp179 in the WPD loop and BB allosteric path-
way (Wiesmann et al., 2004) in the other direction (Figure 5—figure supplement 4). Thus, surface
residues such as Tyr152 may be conformationally coupled to the buried underside of the WPD loop
via a similar mechanism as BB binding – remotely modulating the Trp179 anchor via coordinated
hydrophobic shifts – but from a different angle of attack, via Tyr176. Overall, such coordinated local
shifts within the hydrophobic core likely ‘lubricate’ the transition between discrete global states of
PTP1B.
Assessing the ligandability of the surface of PTP1B using automated
crystallography
Although the results described above establish a conformationally coupled network within the struc-
ture of PTP1B, allosteric inhibition also requires binding sites for small molecules that can conforma-
tionally bias this network to modulate function. To identify potential allosteric ligand-binding sites in
PTP1B, we mapped the small-molecule binding potential or ‘ligandability’ of the entire protein sur-
face. Specifically, we used small-molecule fragments, which by virtue of their small size provide a rel-
atively large sampling of drug-like chemical space (Murray and Blundell, 2010). Astex
Pharmaceuticals has previously explored fragment-based drug design for PTP1B (Hartshorn et al.,
2005); however, that screen used molecules pre-selected to enrich for binders to phosphatase active
sites, which contrasts with our goal of exploring the surface outside of the active site. To determine
cocrystal structures of hundreds of fragments with PTP1B, we used the high-throughput fragment-
soaking and crystallographic pipeline available at Diamond Light Source (Collins et al., 2017) to
individually soak 1918 apo PTP1B crystals with small-molecule fragments in DMSO from several
curated libraries, and another 48 with just DMSO. We then used robotic sample handling to auto-
matically collect complete X-ray datasets at 100 K (Figure 6—source data 1). Of the 1966 total
soaks, 1774 yielded diffraction data that could be successfully processed. The data were generally
high-resolution: the average resolution was 2.1 A˚, 65% of resolutions were better than 2.0 A˚, and
87% were better than 2.5 A˚ (Figure 6A, Figure 6—source data 1). The large number of datasets
enabled us to use the new Pan-Dataset Density Analysis (PanDDA) algorithm (Pearce et al., 2017)
to reveal bound fragments. PanDDA performs weighted subtractions of the ‘background’ electron
density (computed from apo and unbound datasets) from each electron density map (Figure 6B–C).
The optimal subtraction, chosen by a heuristic, yields electron density corresponding to the ligand-
bound fraction of unit cells in the crystal.
Our PanDDA analysis of 1774 datasets revealed 381 putative binding events. We manually
inspected each putative binding event, and were able to confidently model the fragment in atomic
detail for 110 hits (Figure 6D). Overall, 12 different sites in PTP1B were observed to bind fragments
(Figure 6E). These sites are structurally distinct from one another – that is, they share no residues in
common, and fragments bound within different sites do not overlap with each other. They are also
widely distributed across the protein surface. Twenty-five fragments bind to multiple sites, but pro-
miscuous binding is not unexpected from such small fragments, and still provides valuable informa-
tion about favorable binding poses in each site.
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PanDDA initially identified >80 putative binding events in the active site. Many of these can be
attributed to movements of the WPD loop (Figure 2), often induced by oxidation of the catalytic
Cys215, which is a natural regulatory mechanism (van Montfort et al., 2003). Apart from these pro-
tein events and other false positives, we observe four fragments bound in the active site. This num-
ber is relatively low likely because our libraries were not customized to bind to the highly charged
active site of PTP1B, as was the case in the Astex study (Hartshorn et al., 2005).
To identify allosteric binders, we examined sites outside of the active site. Strikingly, we observed
24 bound fragments in the BB allosteric site (Figure 7A). The poses of many of these fragments
overlap portions of the BB scaffold (Figure 7A, Figure 7—figure supplement 1). However, many of
them also contain chemical groups that suggestively protrude in new directions from the BB scaffold
(Figure 7—figure supplement 1). This retrospective result validates the idea that fragment
Figure 6. Electron-density background subtraction reveals small-molecule fragments at allosteric sites in PTP1B. (A) Histogram of X-ray resolution for
1774 structures of PTP1B soaked with small-molecule fragments (gray) vs. the 110 structures from that set with small-molecule fragments bound to
PTP1B (green). (B) For one example fragment, a traditional 2Fo-Fc map contoured at 1.25 s (cyan volume) and at 3.5 s (blue mesh) provides no clear
evidence for a bound fragment. (C) By contrast, a background-subtracted PanDDA event map (85% background subtraction in this case) contoured at
the same levels clearly reveals the precise pose of the bound fragment, plus additional ordered water molecules that accompany it (red spheres). (D)
PanDDA analysis and manual inspection reveal 110 fragment-bound structures of PTP1B, with bound fragments clustered into 12 non-overlapping
binding sites. Some structures contain multiple bound copies of the same fragment. Several sites of interest are labeled. (E) Overview of bound
fragments across the PTP1B surface. Left: front of protein, facing active site (WPD loop open and closed conformations in red). Right: back of protein,
facing several fragment-binding hotspots: the 197 site, BB site, and L16 site. The viewing orientation in E) (left) is as in Figure 1A (‘front side’ of PTP1B).
The viewing orientation in E) (right) is as in Figure 1B (‘back side’ of PTP1B).
DOI: https://doi.org/10.7554/eLife.36307.024
The following video and source data are available for figure 6:
Source data 1. Results of all 1966 fragment and DMSO soaks into PTP1B crystals.
DOI: https://doi.org/10.7554/eLife.36307.026
Figure 6—video 1. Movie version of Figure 6E.
DOI: https://doi.org/10.7554/eLife.36307.025
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screening identifies binding sites, and specific fragment poses in those sites, that can be fruitfully
exploited for allosteric inhibition. Interestingly, in one structure with a fragment bound in the BB
site, the a7 helix adopts a reordered conformation that covers the binding site (Figure 7A), reminis-
cent of other examples in published structures and in our high-temperature datasets (Figure 3—fig-
ure supplement 3). These compounds could also inspire design of modified BB2 derivatives that
may overcome the low affinity that limited the development of that series.
We also examined fragments bound to the L16 site and the 197 site, which were suggested to be
allosteric sites by our multitemperature analysis of apo PTP1B. Excitingly, both sites are fragment-
binding hotspots: 17 fragments bind to the L16 site (Figure 7B) and 30 fragments bind to the 197
site (Figure 7C). Thus, independent methods to assess allosteric coupling and ligandability converge
on the same sites in PTP1B. Our results agree with previous studies, based on mutagenesis and
NMR, which implicated several residues in the L16 site (Cui et al., 2017) and in the 197 site
(Choy et al., 2017; Cui et al., 2017) as participating in an active-site-linked allosteric network. We
also add value to those studies in another way: by reporting the binding poses of a few dozen small-
molecule ligands that bind to these sites in atomic detail. Because these two sites are both confor-
mationally coupled to the active site and capable of binding a variety of small molecules, they may
be promising sites to explore for small-molecule allosteric inhibition of PTP1B activity.
The L16 site is between loop 16 (L16), the beginning of a1, and the end of a6. Most of the 17
fragments that bind here appear to ‘pry apart’ these elements (Figure 7B) to create a cryptic bind-
ing site (Cimermancic et al., 2016a). Because the end of a6 is coupled to the beginning of a7, which
is perhaps the central allosteric hub of PTP1B (Choy et al., 2017), this site seems promising for
Figure 7. Fragments cluster at three binding hotspots distal from the active site. (A) Twenty-four fragments (green) bind to the same site and in similar
poses as the BB2 inhibitor (orange, PDB ID 1t49), and similarly displace the a7 helix (foreground, transparent blue, PDB ID 1sug). BB2 is also shown in
the following panels to emphasize that its binding site is distinct from the other fragment-binding hotspots. One structure with a fragment bound in
this site features a reordered conformation of the a7 helix (pink). (B) Seventeen fragments bind to the L16 site, where they may modulate the
conformations of loop 16, the a6 helix, and the protein’s N-terminus on the a1 helix. (C) Thirty fragments bind to the 197 site in one primary subsite
contacting K197, or a distinct secondary subsite nearby. The viewing orientation in (A) is as in Figure 1B (‘back side’ of PTP1B), except zoomed in on
the BB site (labeled in Figure 1B). The viewing orientation in (B) is also as in Figure 1B, except looking left from the right of that image and zoomed in
on the L16 and BB site site. The viewing orientation in A) is as also in Figure 1B, except zoomed in on the 197 site and BB site (labeled in Figure 1B).
See also Figure 6E (right) for orientation.
DOI: https://doi.org/10.7554/eLife.36307.027
The following source data and figure supplements are available for figure 7:
Source data 1. Crystallographic statistics for fragment-bound structures.
DOI: https://doi.org/10.7554/eLife.36307.030
Source data 2. Small-molecule fragments tested in enzyme inhibition assays.
DOI: https://doi.org/10.7554/eLife.36307.031
Figure supplement 1. Fragments overlap with the BB allosteric inhibitor scaffold and suggest possible improvements.
DOI: https://doi.org/10.7554/eLife.36307.028
Figure supplement 2. Fragments in the 197 site overlay with glycerols from multitemperature structures.
DOI: https://doi.org/10.7554/eLife.36307.029
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allosteric inhibition. The fragments that bind here are diverse but have some common features: aro-
matic moieties sandwich between Pro239 (of L16) and Met282 (a6), and carboxyl groups hydrogen-
bond to the backbone amide of Glu2 (a6). These fragments do not spatially overlap with any frag-
ments in the nearby BB site, confirming that the L16 site is genuinely distinct from the previously
explored allosteric site.
The 197 site is on the opposite side of the BB site, near a3 (including Lys197) and L11 (including
Tyr152). Thirty fragments bind in the 197 site, with 14 in the primary subsite near Lys197, and 17 in a
nearby but distinct subsite separated by a ‘ridge’ formed by the Gln157 and Glu170 sidechains
(Figure 7C) (one fragment binds in both the primary subsite and the secondary subsite). These frag-
ments are characterized by packing of aromatic moieties above Leu172, with additional aromatic or
polar extensions in various directions. As with the L16 site, fragments in this site do not overlap with
any fragments in the nearby BB site. However, several of the fragments in the 197 site do overlap
with the positions of ordered glycerols from our multitemperature structures (which were absent
from all fragment-soaked structures to avoid competition for binding) (Figure 7—figure supplement
2). Similarly, glycerol in PDB ID 3qkp and b-octylglucoside in PDB ID 2cmc (among other examples)
bind to sites that are occupied by fragments in our structures. These findings emphasize that fortu-
itous binding of buffer components and other miscellaneous compounds can in some cases provide
useful information about binding sites (Mattos and Ringe, 1996). It may be possible to link frag-
ments in the primary subsite and secondary subsite to increase binding affinity. Although some frag-
ments in the secondary subsite are largely stabilized by crystal-lattice contacts, they still enjoy
favorable interactions with the protein that could potentially be useful for fragment extension. By
contrast, the primary subsite is generally free from crystal-lattice contacts.
To assess the effect of the bound fragments on the structure of PTP1B more globally, for each
dataset we built an ensemble structure consisting of both the ground state and the bound state.
Each dataset was modeled with an innovative PDB format as a multiconformer structure that repre-
sents both a heterogeneous apo state and a heterogeneous holo state. Due to limitations in the
PDB model format and in the ability of conventional refinement programs to interpret and create
reasonable restraints for this model type, either one conformation or four alternative conformations
were used to describe each residue, often when only two were necessary. Due to this forced degen-
eracy, refinement of coordinates, occupancy, and B-factors must be highly restrained. We interpret
the resulting occupancies as a good approximation of the fraction of unit cells that have a ligand
present. Refining these ensemble structures using restraints that avoid overfitting allowed for some
structural differences between the two states to emerge. In principle, these structural differences
could give some prediction of the functional effects one might expect upon developing a
higher affinity version of the molecule. The refined ensemble structures were of high quality (Fig-
ure 7—source data 1). However, generally speaking, the structural differences were subtle: the
global backbone RMSD (N, Ca, C atoms) between the ground state and bound state ranged from
0.7 to 1.7 A˚. Cases with larger RMSD (>1.25 A˚) generally involved either active-site fragments that
directly shift the WPD loop, or fortuitous oxidation of the active-site Cys215 (van Montfort et al.,
2003). Thus, fragment binding did not dramatically shift PTP1B from the open to the closed state in
many of these structures. Many of these fragments are certainly benign binders that bind to non-
allosteric sites. However, the strong preference for the open state even with fragments that bind to
allosteric sites is likely due to the absence of glycerol, which is present in our multitemperature struc-
tures (see Materials and methods). It is likely that weak fragments do not overcome this energetic
preference, and instead elicit conformational changes primarily in their immediate vicinity. Including
glycerol to place the protein in a regime in which the open vs. closed states are more nearly isoener-
getic during fragment soaks could potentially interfere with fragment binding to the 197 site, since
ordered glycerols also fortuitously bind there (Figure 7—figure supplement 2).
Validating a functional allosteric linkage with covalent tethering
The small-molecule fragments described above were identified by a naive screen and are not opti-
mized for high-affinity binding to the 197 site or L16 site of PTP1B. Nevertheless, we selected 20
fragments that were deemed to bind in either site during early rounds of iterative PanDDA analysis
(see Materials and methods) (Figure 7—source data 2) and tested whether they have allosteric
effects using enzyme activity assays. Unsurprisingly, we did not observe inhibition of enzyme activity
by the fragments up to the maximum concentrations we were able to assay due to solubility of the
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fragments. It is important to note that this is not surprising due to the fragments’ small sizes, rela-
tively simple chemical structures, and low affinities (soaking with fragments at 30–150 mM concen-
trations resulted in observed occupancies of only 10–30% in the crystal structures). However, looking
ahead, the dozens of cocrystal structures with small-molecule fragments bound at these promising
allosteric sites (and at the previously explored BB2 site) that we have reported here offer a foothold
for future medicinal chemistry efforts to design allosteric inhibitors for PTP1B.
Instead, here we focus on an alternative strategy to validate the concept of allosteric inhibition at
the 197 site: covalent binding to enhance ligand occupancy. Specifically, we used ‘Tethering’
(Erlanson et al., 2000; Erlanson et al., 2004), in which a residue near the site of interest is mutated
to cysteine, then the mutant is mixed with disulfide fragments under partially reducing conditions.
Affinity of the fragments for the site of interest drives the formation of a disulfide bond between the
fragment and the adjacent cysteine. The extent of cysteine labeling can be measured using whole-
protein mass spectrometry, and serves as a metric to rank the affinity of fragments for a given site.
One major advantage of Tethering over other fragment-based approaches is that it can leverage
low-affinity binding events into quantitatively labeled protein species, whose enzymatic activity can
then be assayed. Here, we used Tethering to successfully identify a covalent allosteric inhibitor at
the 197 site of PTP1B (Figure 8).
For the allosteric 197 site in PTP1B, we chose to tether to a K197C mutant for several reasons.
First, K197 is on the a3 helix, which is a key allosteric element in PTP1B (Choy et al., 2017). We pre-
dicted that small-molecule tethering to our site could could perturb the helix via K197C, perhaps
mimicking the effects of a free molecule binding to the WT protein and altering the K197 conforma-
tional distribution. Second, K197 and E200 are the two residues on a3 whose Ca-Cb vectors point in
roughly the correct direction toward the allosteric 197 site we describe; however, E200 engages in
crystal-lattice contacts which would interfere with tethering in our P3121 space group, so we focused
on K197C instead.
To efficiently explore the chemical space of covalent small molecules for the 197 site, we used a
library of 1600 disulfide-capped fragments designed for covalent tethering experiments
(Kathman et al., 2014; Burlingame et al., 2011a). From our initial screen, we identified 50 frag-
ments that tethered to K197C > 3 standard deviations above the average percent tethering for all
1600 compounds (Figure 8—figure supplement 1A). We next measured the ability of these top
fragments to modulate PTP1B’s phosphatase activity (Figure 8—figure supplement 1B). Formation
of the tethered complex followed by a pNPP assay identified only one fragment, 1 (Figure 8—figure
supplement 1C), that appeared to inhibit PTP1B at a percentage comparable to the percentage of
tethered complex (Figure 8—figure supplement 1B), suggesting a direct relationship between
labeling and inhibition. While 1 thus showed the behavior we desired, the percent labeling and inhi-
bition were relatively low. We hypothesized that altering the linker between the fragment core and
the disulfide bond may lead to improved interactions between the protein and small molecule. For
this reason, we designed and synthesized 2 (Figure 8A), which has the orientation of the amide
bond reversed, allowing for one less carbon in the disulfide linker (Figure 8—figure supplement
1C).
When assayed, 2 showed improved tethering and inhibition of K197C relative to 1. 2 exhibited
dose-dependent tethering and partial noncompetitive allosteric inhibition of K197C with a tethering
EC50 of 7.8 ± 1.1 mM and a Ki for pNPP activity of 7.1 ± 1.1 mM (maximum inhibition of ~60%)
(Figure 8B and Figure 8—figure supplement 2A). Importantly, 2 appeared to show little to no teth-
ering of WT* and minimal inhibition, supporting that 2’s activity is specific to the 197 site and not
due to tethering of the active-site cysteine found in both K197C and WT/WT* (Figure 8C and Fig-
ure 8—figure supplement 2B). In fact, the inhibition that is observed for WT* does not correlate
with tethering, suggesting the inhibition may be from nonspecific factors, such as aggregation, at
higher concentrations of 2 (50 mM). Michaelis-Menten kinetic analysis of K197C in the presence of
2 (50 mM) showed a statistically significant ~50% reduction in Vmax relative to DMSO treatment, but
no significant effect on KM for the pNPP substrate (Figure 8—figure supplement 2C,E,F). This sup-
ports a noncompetitive allosteric mechanism of inhibition. The effect on WT* kinetics was similar to
the nonspecific inhibition observed in the dose titration experiment (Figure 8—figure supplement
2D), once again supporting that the activity of 2 is specific for the K197 site on PTP1B. To further
profile the inhibitory effect of tethering of 2 on K197C, we assayed the ability of the tethered com-
plex to dephosphorylate the alternative substrate DiFMUP (Welte et al., 2005). As with pNPP, the
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Figure 8. Characterization of a functional covalent allosteric inhibitor. (A) The chemical structure of our covalent
disulfide fragment 2. (B) Tethering and Inhibition of K197C at varying concentrations of 2. The tethering EC50
observed was 7.8 ± 1.1 mM and the Ki for pNPP activity was 7.1 ± 1.1 mM with a maximum inhibition of ~60%.
Tethering data represents all tethering events combined. (C) Tethering and Inhibition of WT* at varying
concentrations of 2. The tethering EC50 and the Ki for pNPP activity were both >50 mM. Tethering data represents
all tethering events combined. Data represent the mean of three independent assays ± the standard error of the
mean. All assays were performed in the presence of 100 mM of b-mercaptoethanol.
DOI: https://doi.org/10.7554/eLife.36307.032
The following figure supplements are available for figure 8:
Figure supplement 1. Identification of a functional covalent allosteric inhibitor.
DOI: https://doi.org/10.7554/eLife.36307.033
Figure supplement 2. 2 tethers to only a single cysteine in K197C and inhibits through a reduction in Vmax.
DOI: https://doi.org/10.7554/eLife.36307.034
Figure supplement 3. 2 inhibits K197C catalysis of DiFMUP through a reduction in Vmax.
DOI: https://doi.org/10.7554/eLife.36307.035
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tethered complex was inhibited, with kinetic analysis showing a dramatic reduction in Vmax, but no
significant effect on KM (Figure 8—figure supplement 3). These results once again support a partial
noncompetitive allosteric mechanism of inhibition.
To futher validate that 2 acts specifically through the K197 site and to explore the mechanism of
inhibition by 2, we solved a high-resolution (1.95 A˚, Table 1) crystal structure of K197C tethered
with 2. The structure confirms that 2 tethers to K197C rather than to the active-site catalytic Cys215,
and also that tethered 2 resides in the 197 site (Figure 9A) rather than in the relatively nearby BB
site, which is also theoretically within reach of the tethering linker on the other side of the a3 helix.
We modeled 2 as partially populated and, indeed, the 83% refined occupancy in the crystal structure
was very similar to the ~85% conjugation measured after tethering in solution prior to crystallization.
2 adopts a conformation in which the two rings are nearly coplanar. This interpretation is further vali-
dated by a ‘polder map’, in which both the ligand and bulk solvent are omitted (Liebschner et al.,
2017) (Figure 9—figure supplement 1). While coplanar biphenyl rings are typically believed to be
disfavored due to steric clashes, it is possible that hydrogen bonding of D148 with the phenol com-
bined with the electronegativity of the para-fluoro leads to delocalization of the rings’ electrons and
promotes a coplanar conformation. Additionally, 2 packs against the hydrophobic floor, centered on
Leu172, of the relatively shallow binding pocket in the 197 site. Trapping of coplanar biphenyl rings
covalently attached to a protein has previously been reported (Pearson et al., 2015).
To elucidate confomational changes induced by 2, we also solved a high-resolution (1.95 A˚,
Table 1) crystal structure of apo K197C in the same crystal form for comparison. As mentioned previ-
ously, PTP1B remains in the open state without glycerol; glycerol was absent from the tethered
K197C structure (to avoid competition for binding in the 197 site) and from the K197C apo structure
(for consistency), so we are unable to see any dramatic shifts in the global open-closed equilibrium
that 2 may induce. Tyr153 shifts its position slightly and Tyr152 responds by shifting fully to its up
rotamer, but this is likely due to the loss of interactions with the WT K197 upon mutation. Beyond
these mutation-induced effects, we see some conformational changes associated with tethering of
2. The key residue Asn193 (Choy et al., 2017) changes rotamers, the sidechain of Phe196 on a3
‘slides’ to change its aromatic stacking arrangement with Phe280 on a6 (Figure 9C), and Glu276 –
which contacts the wedge residue Leu192 (Choy et al., 2017) – rotates sidechain dihedral angles.
These sidechain movements appear to couple to subtle, more distributed backbone shifts
(Deis et al., 2014) of the a3 helix, several residues of which move up toward the WPD loop by ~0.5
A˚ (Figure 9C). Interestingly, these sidechain and particularly backbone movements are somewhat
similar to those between the two macrostates of apo PTP1B at high temperature (Figure 9D). Thus,
although the mechanistic details remain unclear, allosteric inhibition by 2 may involve conformational
changes, especially of a3, that are similar to those that occur during the global transition from the
open to the closed state (Choy et al., 2017). This interpretation is consistent with a recent report
that mutations (Y153A, M282A) in what we here recognize as the 197 site and L16 site alter the equi-
librium between the WPD loop’s open and closed states (Cui et al., 2017). We note that the non-
competitive allosteric mechanism observed suggests that tethering 2 to K197C may shift the pro-
tein’s energy landscape in such a way as to alter the kinetics of WPD loop motions. Future work to
explore this issue would nicely complement the crystallographic and functional analysis we provide
here.
Interestingly, several of the other noncovalent fragments bound to WT* overlay well with the aro-
matic rings of 2 tethered to K197C (Figure 9B). This structural convergence suggests promising new
avenues for future medicinal chemistry efforts. First, more conservatively, portions of specific frag-
ments could be added to 2 to yield improved covalent allosteric inhibitors for K197C PTP1B. Sec-
ond, perhaps more promisingly, portions of 2 could be combined with (portions of) specific
fragments to create potent new non-covalent allosteric inhibitors for WT PTP1B.
Discussion
Our analysis of PTP1B paints a portrait of an inherently allosteric system. Allostery is fundamentally
tied to protein functions such as catalysis via the theme of conformational motions (Goodey and
Benkovic, 2008). Here, we have harnessed new approaches in X-ray crystallography to map coordi-
nated conformational redistributions that underlie allostery in the dynamic enzyme PTP1B.
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Figure 9. A functional small-molecule inhibitor tethered to the allosteric 197 site. (A) The tethered inhibitor 2 is highly ordered (~85% occupancy) in the
197 site, as seen by 2Fo-Fc electron density for our 1.90 A˚ structure contoured at 0.75 s (cyan volume) and at 1.5 s (blue mesh) that is continuous to the
K197C sidechain. A few waters (transparent red spheres) which appear to be mutually exclusive with the molecule are likely displaced by binding. (B)
Many fragments from WT* cocrystal structures (transparent orange) overlay well with 2 in the K197C cocrystal structure (green). One fragment in
Figure 9 continued on next page
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Metaphorically, we were able to use this map of PTP1B’s ‘intramolecular nervous system’ to reveal
allosteric ‘pressure points’ that enable long-range modulation of its function.
Proteins sample many conformations from a complex energy landscape (Frauenfelder et al.,
1991), many of which are accessible and represented among the millions to trillions of molecules in
a protein crystal. However, an X-ray crystallographic dataset provides only ensemble-averaged infor-
mation – so it is difficult to decipher individual minor conformations from a single dataset. A key to
our work was harnessing the power of en masse structural analysis, which let us reveal minor confor-
mations and the shifts between them that allow a dynamic protein to function. We exploited families
of structures in two different ways. First, we contrasted structures at several different temperatures
(Keedy et al., 2015b) for PTP1B to track coordinated conformational shifts which underlie allosteric
communication. Second, we used hundreds of structures of PTP1B with different small-molecule
fragments to calculate a statistical ‘background’ electron density map representing the unbound
state, which we could subtract to reveal fragment-bound conformations (Pearce et al., 2017) for
many allosteric sites. This requires using the PDB format of alternative locations to encode both
compositional and conformational heterogeneity within a single model. Our multi-structure equilib-
rium X-ray approaches complement other methods for breaking the degeneracy of ensemble-aver-
aged data to resolve multiple conformations of macromolecules. For example, 3D classification
algorithms in cryo-electron microscopy enable in silico purification of different compositional and
conformational states (Scheres, 2016). Time-resolved X-ray experiments, for example with free-elec-
tron lasers, offer great promise for mapping conformational changes with both spatial and temporal
resolution, although general experimental strategies are still forthcoming for the vast majority of
proteins that are non-photoactivatable (Hekstra et al., 2016). More generally, integrative modeling
algorithms can synthesize data from disparate sources at different resolutions, including solution
NMR or small-angle X-ray scattering, to build ensembles of structures that are consistent with all the
experimental data (van den Bedem and Fraser, 2015; Russel et al., 2012).
By exploiting a new multitemperature multiconformer X-ray approach, we have identified a col-
lective allosteric network that is contiguous on the ‘back side’ of the protein, centered around the
quasi-ordered a7 helix (Figure 2E, Figure 9E). This network includes the BB site, which was previ-
ously targeted with a small-molecule allosteric inhibitor (Wiesmann et al., 2004). It also includes
adjacent sites (the 197 site and the L16 site) in either direction from the BB site, which have not
been targeted previously with small-molecule inhibitors. Several residues in these additional sites
were implicated as being part of putative allosteric sites by recent work using mutagenesis and
NMR chemical shift and dynamics information (Choy et al., 2017; Cui et al., 2017). Our work agrees
with those studies in identifying the 197 site and L16 site as potentially important players in PTP1B’s
collective allosteric network. We additionally complement them by revealing, in atomic detail, alter-
native conformations that these sites natively populate. Our work suggests that allosteric perturba-
tions do not necessarily induce conformational changes in PTP1B – instead, the alternative
conformations are already latently sampled by the apo protein and are simply stabilized by the allo-
steric perturbations. Portions of the allosteric network we observe here in PTP1B – in particular the
series of aromatic and hydrophobic residues linking the allosteric BB site to the active site (Figure 3)
Figure 9 continued
particular (solid orange) has a ring substructure that overlays very closely with a ring substructure of 2. (C) The K197C 2-tethered structure (green) is
similar to the K197C apo structure (gray), but upon tethering there are several conformational changes (arrows and asterisk) in the a3 helix: the whole
backbone shifts up in this view slightly leading back into the WPD loop (top), N193 switches rotamers, and the sidechains of F196 and E200 move within
rotameric wells. The end of the a6 helix, including E276 and F280, appears to respond in concert. (D) Several of these changes mirror changes from
open-to-closed apo PTP1B (arrows and asterisk) as seen in the two conformations of our 278 K model (red/orange). (E) Overview as in Figure 2E for
context. The viewing orientation in (A) is as in Figure 1B (‘back side’ of PTP1B), except zoomed in on the 197 site (labeled in Figure 1B). The viewing
orientation in (C–E) is as in Figure 1B.
DOI: https://doi.org/10.7554/eLife.36307.036
The following video and figure supplement are available for figure 9:
Figure supplement 1. Polder omit map of K197C tethered structure.
DOI: https://doi.org/10.7554/eLife.36307.037
Figure 9—video 1. Movie version of Figure 9A.
DOI: https://doi.org/10.7554/eLife.36307.038
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and the cluster of aromatic residues behind and beneath the WPD loop (Figure 5—figure supple-
ment 4) – are analogous to the dynamic hydrophobic spines that play central roles in allosteric acti-
vation of protein kinases (Taylor and Kornev, 2011; Kim et al., 2017). Our analysis suggests that
allostery in PTP1B is characterized by interdependent conformational changes spanning length
scales: helical order-disorder transitions, hydrophobic shifts, local sidechain rotamer changes, subtle
helical twists, and large discrete active-site loop motions.
Our work reveals new opportunities for long-range control of PTP1B function by impinging upon
tendrils of this expanded allosteric network with small molecules. Specifically, we have used two dif-
ferent small-molecule techniques with complementary strengths to reveal new footholds for devel-
oping allosteric inhibitors for PTP1B in the future. First, we used a new high-throughput method
with small-molecule fragments to map the ligandability of the entire surface of PTP1B with high
structural resolution. Although individually these fragments have low affinity, collectively the 110
protein:fragment structures we report reveal overlapping poses with a multitude of precise binding
interactions at specific sites in PTP1B (Figure 7A,B,C). Many of the 11 binding sites outside the
active site are likely to be benign. Importantly, our multitemperature X-ray analysis of the apo pro-
tein provides a way to predict which binding sites are instead likely to be allosterically coupled to
function. Based on the result that the same small number of sites are both (a) implicated as allosteric
by multitemperature X-ray analysis of conformational changes in apo PTP1B and (b) the most ligand-
able sites from the fragment screen across the entire surface, we conclude that conformational
changes may be important for allosteric ligand binding in this protein. Second, we used covalent
tethering to probe the functional effects of a high-occupancy ligand at one promising allosteric site.
Our work takes advantage of a synergy between fragments and tethering. Fragments bind weakly,
but allow for the visualization of hundreds of chemical entities bound to distinct sites in a protein. By
contrast, tethering does not provide high-throughput structural information, but allows for targeted
perturbations to functionally probe a specific site, and additionally can provide lower-throughput
structural information about chemical matter that allosterically inhibits a protein variant. Importantly,
the structural and functional information from these techniques can be combined to open doors for
future structure-based drug design efforts (Figure 9B). Together, our results illuminate a promising
new region of chemical space that may be fruitfully explored by future medicinal chemistry efforts to
develop potent non-covalent allosteric inhibitors for WT PTP1B.
Although our work helps set the stage for such efforts, generating potent and selective ligands
based on linking of fragment-screening hits is a difficult and time-consuming process that is beyond
the scope of this current study. While none of the fragments identified to bind at the 197 site in our
work have the potency or selectivity for proper assaying of their effect on enzyme activity, let alone
for use as a cell-active ligand, their identification supports the ligandability of the 197 site, and moti-
vates future efforts to identify potent ligands at this site. Our use of covalent tethering at the 197
site allowed us to drive occupancy of fragment 2 at this site and functionally validates the allosteric
effect of ligand binding at this site on PTP1B phosphatase activity. The percent tethering observed
for 2 is correlated with the percent inhibition observed (Figure 8B), indicating that the tethered
compound drives inhibition. However, the maximum inhibition is only ~60% (Figure 8B and Fig-
ure 8—figure supplement 3A), which is consistent with a partial noncompetitive allosteric mecha-
nism of inhibition. This mechanism is supported by our kinetic analysis of 2-bound K197C
(Figure 8—figure supplement 2C and Figure 8—figure supplement 3B) where the reduction in
enzyme rate is driven by a reduction in Vmax, not a change in KM(Figure 8—figure supplement 2E,F
and Figure 8—figure supplement 3C,D). Partial inhibition is a common paradigm in noncompetitive
allosteric inhibition, where ligand occupancy does not perfectly correlate with inhibition
(Ramsay and Tipton, 2017; Whiteley, 2000).
The ‘druggability’ of the 197 site in WT PTP1B is further supported by recent work using struc-
ture-based simulations and virtual screening, which found that the 197 site bound several diverse
molecules in silico, and was the most responsive to allosteric perturbations among several potential
allosteric pockets identified in PTP1B (Kumar et al., 2018). Together with our findings, these data
imply that while the development of potent non-covalent allosteric inhibitors targeting the 197 site
may be arduous, a concerted effort toward this goal may ultimately be fruitful.
Future efforts to develop potent non-covalent allosteric inhibitors for PTP1B can explore an addi-
tional feature of the allosteric 197 site that may enhance its druggability. As stated above, the quasi-
disordered a7 helix is capable of reordering into different conformations, some of which cover the
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a3-a6 region including the 197 site. We observe several reordered a7 conformations under different
conditions: with BB3 at 273 K, with BB1 at 100 K, in the S295F (a7) mutant, in the L192A (a3) mutant
with an active-site inhibitor (Figure 3—figure supplement 3C), and with a fragment in the BB site
(Figure 7A). Similarly, the disordered C-terminus, including a7, accommodates a recently reported
allosteric inhibitor (Krishnan et al., 2014). For the BB site, the malleability of a7 is likely a double-
edged sword. On one hand, reordered conformations of a7 may contribute binding energy to allo-
steric inhibitors by forming a ‘lid’ over what is partially a ‘cryptic site’ (Cimermancic et al., 2016). On
the other hand, they may also accommodate different small-molecule variants equally well, such that
it is difficult to improve upon inhibition – that is, the structure-activity relationship (SAR) is flat. How-
ever, the 197 site is structurally distinct from the BB site, and is accessible to different, more C-termi-
nal portions of a7. Future work will test the hypothesis that the 197 site can yield improved allosteric
inhibitors that take advantage of these unique structural features. Notably, it is possible that the flat
SAR observed at the BB site is due to an inhibition mechanism that is unrelated to the particular
binding site, which is not uncommon in PTP1B drug discovery efforts – if this is the case, targeting
the 197 site may face similar hurdles.
Our work motivates specific future efforts to allosterically inhibit PTP1B activity for therapeutic
purposes. However, the allosteric network illuminated here by probing PTP1B with non-biological
perturbations (temperature and small molecules) in vitro may also be relevant to how the enzyme is
regulated in vivo, in at least three ways. First, in addition to directing subcellular localization
(Frangioni et al., 1992), the quasi-disordered C-terminal region of PTP1B reorders to interact with
the ‘back side’ of the catalytic domain in different ways, is phosphorylated at disordered serine resi-
dues in vivo to regulate function (Brautigan and Pinault, 1993), and mediates allosteric inhibition by
natural product molecules (Krishnan et al., 2014). Moreover, removing a7 reduces activity in PTP1B
(Choy et al., 2017), and removing the disordered C-terminus in the related phosphatase TCPTP
reduces activity even more dramatically (Hao et al., 1997). Second, Tyr152 (Figure 5) is phosphory-
lated in vivo, which contributes to binding to the insulin receptor kinase (IRK)
(Bandyopadhyay et al., 1997; Rhee et al., 2001) and is required for binding to N-cadherin
(Bandyopadhyay et al., 1997; Rhee et al., 2001). Tyr152 phosphorylation is sterically compatible
only with the ‘up’ rotamer, which is correlated with the global open state of PTP1B; it is therefore
possible that Tyr152 phosphorylation and/or subsequent IRK or cadherin binding events directly
affect PTP1B activity via the allosteric network we report here. Third, in several other protein tyrosine
phosphatases (PTPs), protein-protein interactions occur on the ‘back side’ of the catalytic domain –
coinciding with where we observe three major allosteric sites in PTP1B. For example, in RPTPg and
RPTPe, the non-catalytic D2 domain binds to the catalytic D1 domain at an interface coinciding with
the allosteric network we report on the back of PTP1B (Barr et al., 2009). Additionally, the N-termi-
nus of PTPL1 wraps around the area coinciding with the L16 site in PTP1B, and docks in the area
coinciding with the a7 helix in PTP1B (Villa et al., 2005). Together, these observations suggest that
the allosteric network we establish here within the catalytic domain of PTP1B may function as a
‘receiver’ for allosteric inputs from the C-terminus in cells. If so, this strategy operates in parallel with
other mechanisms such as active-site oxidation (van Montfort et al., 2003) and phosphorylation of
other sites in the catalytic domain (Ravichandran et al., 2001) as part of a complex, multifaceted
regulatory scheme.
Finally, it is interesting to note that different protein tyrosine phosphatases (PTPs) share a struc-
turally conserved catalytic domain with PTP1B – but have different variants of the a7 helix or even
entirely different N- or C-terminal domains (Alonso et al., 2004) that can be trapped in inhibitory
conformations for allosteric inhibition, as recently realized for SHP2 (Chen et al., 2016). Similarly,
regulatory domains or subdomains were recently targeted for allosteric inhibition of the serine/thre-
onine phosphatases Wip1 (Gilmartin et al., 2014) and PP1 (Carrara et al., 2017). It will be exciting
to dissect the mechanisms by which different PTPs are allosterically controlled by their specific regu-
latory domains – both to unravel these proteins’ unique cellular roles, and to reveal new opportuni-
ties to correct their dysregulation in disease.
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Materials and methods
Cloning, expression, and purification
For all ‘wild-type’ PTP1B experiments here, we used what we refer to as the WT* construct: residues
1–321, with the C32S/C92V double mutation (Erlanson et al., 2003) to prevent off-target tethering
reactions, in a pET24b vector with a kanamycin resistance gene. K197C, K197A, Y152G, and Y153A
were created using site-directed mutagenesis from the WT* construct.
Protein was expressed and purified as previously reported (Pedersen et al., 2004), with some
minor variations. For expression, we transformed BL21 E. coli cells with plasmid, grew cells on
LB + kanamycin plates overnight at 37˚C, inoculated 5 mL starter cultures of LB + kanamycin with
individual colonies, grew shaking overnight at 37˚C, inoculated larger 1 L cultures of
LB + kanamycin, grew shaking at 37˚C until optical density at 600 nm was approximately 0.6–0.8,
induced with 100 mM IPTG, and grew shaking either for 4 hr at 37˚C or overnight at 18˚C. Cell pel-
lets (‘cellets’) were harvested by centrifugation and stored at  80˚C in 50 mL conical tubes.
For purification, we first performed cation exchange with an SP FF 16/10 cation exchange column
(GE Healthcare Life Sciences) in lysis buffer (100 mM MES pH 6.5, 1 mM EDTA, 1 mM DTT) with a
multi-stage 0–1 M NaCl gradient (shallow at first for elution of PTP1B, then steeper); PTP1B eluted
around 200 mM NaCl. We then performed size exclusion with a Superdex 75 size exclusion column
(GE Healthcare Life Sciences) in size exclusion buffer (100 mM MES pH 6.5, 1 mM EDTA, 1 mM DTT,
200 mM NaCl). PTP1B appeared highly pure in SDS-PAGE gels.
Crystallization
WT* PTP1B was dialyzed into crystallization buffer (10 mM Tris pH 7.5, 0.2 mM EDTA, 25 mM NaCl,
3 mM DTT) with at least a 200x volume ratio overnight at 4˚C. We were unable to grow apo WT*
PTP1B crystals initially, so we synthesized the active-site inhibitors OBA and OTP as in
(Andersen et al., 2002) (OBA = compound 3a, OTP = compound 12h). We were unable to solubi-
lize OTP as used in (Pedersen et al., 2004). Instead, we co-crystallized PTP1B with OBA
(Andersen et al., 2000). We first solubilized OBA to 250 mM in DMSO, then created a 10:1 molar
ratio of PTP1B:OBA. Crystallization drops were set in 96-well sitting- or hanging-drop format at 4˚C
with 10–15 mg/mL protein with 1 mL of protein solution + 1 mL of well solution (0.2–0.4 M magne-
sium acetate, 0.1 M HEPES pH 7.3–7.6, 12–17% PEG 8000), then trays were incubated at 4˚C. Crys-
tals several hundred mm long grew within a few days, and often continued to grow bigger for
several more days. We created seed stocks from these crystals by pipetting the entire drop into 50
mL of well solution, iterating between vortexing for 30 s and sitting on ice for 30 s several times, and
performing serial 10-fold dilutions in well solution. Apo crystals were grown by introducing seed
stock (0x, 10x, or 100x diluted) into freshly set drops, either by streaking with a cat whisker or pipet-
ting a small amount (e.g. 0.1 mL into a 2 mL drop). Serial seeding using new apo crystals successively
improved crystal quality. We also added ethanol to the well solution based on an additive screen
(Hampton Research), and added glycerol to mimic the previously published apo structure protocol
(Pedersen et al., 2004), resulting in the following final WT* PTP1B crystallization well solution: 0.3 M
magnesium acetate, 0.1 M HEPES pH 7.5, 0.1% b-mercaptoethanol, 16% PEG 8000, 2% ethanol,
10% glycerol. The resulting crystals were used for our WT* PTP1B multitemperature analysis.
We also crystallized WT* PTP1B in MRC SwissCi 3-well sitting-drop trays. Protein was at 30–50
mg/mL protein in the same crystallization buffer. The well solution was very similar except for having
a slightly lower precipitant concentration (13–14% PEG 8000) and no glycerol. Drops were set at
room temperature with 135 nL protein solution + 135 nL well solution + 30 nL seed stock, then trays
were incubated at 4˚C. Crystals appeared within a few days. The best seed stocks had been diluted
10-100x. These crystals were used for the BB3-soaking and fragment-soaking experiments.
We crystallized apo K197C in the microbatch format with Al’s oil covering all wells. Protein was at
5–30 mg/mL in the same crystallization buffer as WT* but without DTT. The well solution was 0.3 M
magnesium acetate, 0.1 M HEPES pH 7.5, 0.1% b-mercaptoethanol, 10–26% PEG 8000, 2% ethanol.
Drops were set on ice with 1 mL protein solution + 1 mL well solution, then trays were incubated at
4˚C. Crystals appeared within a few days. We also grew apo K197C crystals in a few other similar
conditions.
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We crystallized K197C tethered to 2 in the 96-well hanging-drop format. Protein was at 15 mg/
mL in the same crystallization buffer as WT* but without DTT. The well solution was 0.2 M magne-
sium acetate tetrahydrate, 20% PEG 3350. Drops were set at room temperature with 100 nL protein
solution + 100 nL well solution, then trays were incubated at 4˚C. Crystals appeared within a few
days.
X-ray data collection
We used PDB ID 1sug for the apo WT 100 K dataset. The apo WT* 278 K dataset was collected at
Stanford Synchrotron Radiation Lightsource (SSRL) beamline 12–2. All fragment-soaked datasets
were collected at Diamond Light Source beamline I04-1. All other datasets were collected at
Advanced Light Source (ALS) beamline 8.3.1.
For apo WT* 180, 240, and 278 K, crystals had been grown in 2 mL drops with 10% glycerol in the
mother liquor, then 1.5 mL of 50% glycerol was added several hours before data collection, resulting
in a final concentration of ~27% glycerol. Some crystals were also dabbed into more 50% glycerol
just before mounting.
For BB3-complexed WT*, crystals were soaked with 125 nL of 10 mM BB3 (in DMSO). No glycerol
was present in these crystals.
For apo WT* and BB3-complexed WT*, crystals were looped and placed in a plastic capillary
with ~70% mother liquor,~30% water to prevent dehydration during data collection, regardless of
temperature; datasets were obtained at different temperatures simply by adjusting the cryojet tem-
perature before placing the crystal on the goniometer. Helical data collection (translation along the
crystal coupled to goniometer rotations) was used to expose fresh regions with each shot, to mini-
mize radiation damage.
For apo and 2-tethered K197C, crystals were simply looped and directly mounted on the goniom-
eter in front of the cryojet. For apo K197C, a small amount of ice was likely present on the crystal.
For fragment-soaked PTP1B, WT* PTP1B crystals in MRC SwissCi 3-well sitting-drop trays were
soaked with small-molecule fragments using acoustic droplet ejection technology and a database
mapping individual fragments to individual crystals as described (Collins et al., 2017). PTP1B crystals
were quite tolerant to DMSO, so we were able to achieve high fragment concentrations and long
incubation times: we soaked overnight for >8 hr at final concentrations of 30% DMSO and 30–150
mM fragment (depending on the concentration of the fragments in the source library). Additionally
we collected X-ray data for 48 ‘apo’ datasets (soaked with DMSO), 42 of which gave high-resolution
datasets, to better establish the unbound background electron density for PanDDA analysis. Despite
the high DMSO concentrations, we did not observe difference electron density consistent with any
ordered DMSO molecules bound to PTP1B. Some fragments were soaked into additional crystals if
good datasets were not obtained from the initial soak; however, only 2 of the 110 fragment-bound
datasets contain the same fragment. We also collected a relatively small number of trial datasets
(28) near room temperature instead of cryogenic temperature, but they were generally low-resolu-
tion, and none revealed bound fragments.
Most crystals stuck to the bottoms of wells regardless of construct and tray format, but it was
often possible to gently dislodge them, or to physically break them off then expose the unperturbed
portion of the crystal to the X-ray beam. Each dataset in this study was collected from a single
crystal.
X-ray data processing
To process the multitemperature and tethered datasets, we used XDS (Kabsch, 2010). In each case
we chose a resolution cutoff for which CC1/2 (Karplus and Diederichs, 2012) was statistically signifi-
cant at the 0.1% level (above 0.4). We created a new set of Rfree flags for the 278 K WT* apo dataset,
then transferred them to the MTZ file of every other dataset with the reflection file editor in PHENIX
(Adams et al., 2010) (for PDB ID 1sug, we first deleted the existing Rfree flags). We solved each
structure by molecular replacement with Phaser (McCoy et al., 2007). One solution was obtained
for each dataset. For WT*, we used PDB ID 1c83 with all waters and the WPD loop removed. For
K197C, we used a refined WT* PTP1B model for molecular replacement.
For fragment-soaked datasets, we used XDS and a custom script [80; copy archived at https://
github.com/elifesciences-publications/xds_iter] to automatically determine resolution cutoffs for all
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datasets. The resolution cutoff was initialized at 1.4 A˚ and incremented until the following criteria
were met for the highest-resolution bin: at least 1.0 I/s(I), at least 50% CC1/2 (Karplus and Dieder-
ichs, 2012), and at least 90% completeness. Rfree flags were created for the highest-resolution data-
set by transferring and extending the flags from the 278 K WT* apo dataset using the PHENIX
reflection file editor. These Rfree flags were then transferred from that highest-resolution dataset to
every other dataset in the fragment-soaking experiment. For PanDDA to accept the MTZ files as
inputs, it was necessary to modify each file so that all columns (H, K, L, structure factors, map coeffi-
cients, and R-free flags) had the same number of indices; no observations were omitted in this step.
We then phased each dataset with Phaser using a reference model that was created by interpreting
a high-resolution DMSO-soaked apo dataset. Next, we refined each initial model from Phaser using
phenix.refine with the following flags to prevent excessive coordinate drift: ‘reference_coordinate_r-
estraints.enabled=True ‘reference_coordinate_restraints.sigma=0.1’. Structure factors were then
dropped from MTZ files, leaving map coefficients as inputs to PanDDA. Filled map coefficients (from
PHENIX) were used to avoid Fourier series truncation effects in PanDDA maps. The resulting models
were used as input to PanDDA (see below).
Structure modeling
For Figure 2—figure supplement 1, we re-refined the following 36 structures of PTP1B from the
PDB either as-is, or with a dual-conformation WPD loop: 1bzj 1kak 1oem 1oeo 1sug 1t48 1t49 1t4j
2azr 2b07 2bgd 2f6f 2f6t 2f6v 2f6w 2f6y 2f6z 2f70 2f71 2h4k 2hb1 2qbp 2qbq 2qbr 2qbs 2zmm
2zn7 3cwe 3d9c 3eax 3eb1 3eu0 3i7z 3i80 3sme 4i8n. For the dual-conformation refinements, we
constrained occupancies of the open + closed conformations of the WPD loop to 1.
For multitemperature WT/WT*, we refined the initial model using phenix.refine for 10 macro-
cycles with automated water picking turned off. Next, we inserted preliminary open and closed alter-
native conformations for the WPD loop, and refined for another 10 macrocycles with automated
water picking turned on. Finally, we performed several rounds of manual rebuilding, including man-
ual addition and deletion of protein, solvent, and glycerol conformations and refinement with auto-
mated water picking turned off. Anisotropic B-factors were not used in refinement. The a7 helix was
modeled as alternative conformation A only, with the unmodeled B conformation presumed to cor-
respond to the disordered state; this allowed the occupancy of the ordered state to be refined. It
was necessary to provide explicit occupancy parameter files to phenix.refine in some cases. For
many residues, conformations obtained from PDB ID 1sug or 1t49 or another of our datasets (usually
higher temperatures) were useful for ‘filling in’ missing density. Often the missing conformations
would not have been obvious based on the map alone, but once inserted and refined they seemed
to fit well. This cross-dataset conformational-sampling approach also had the effect of emphasizing
differences between models from different temperatures while minimizing differences due to chance
or arbitrary modeling choices. Nevertheless, we encourage future users of these datasets to com-
pare across different temperatures based at least in part on the electron density, and not just our
models. The building process was guided by all-atom structure validation with MolProbity
(Chen et al., 2010). The 100 K WT model (1sug) is truly WT, whereas our new WT* datasets are all
C32S/C92V, as noted above; however, both cysteine-scrubbing mutations are structurally conserva-
tive, distal to the active site, and apparently uncoupled from the WPD loop and all allosteric regions.
Glycerol (~20% final) was present in WT* crystals during each multitemperature data collection to
maintain consistency with the 100 K WT structure (PDB ID 1sug), in which glycerol was used as a
cryoprotectant. Several ordered glycerol molecules, including those in contact with the closed WPD
loop and at the allosteric 197 site, were evident from electron density at all temperatures. However,
in some cases, it was difficult to differentiate between ordered waters, glycerols, or simply noise in
the map. For example, the electron density was uncertain at some of the elevated temperatures for
some glycerols originally modeled in PDB ID 1sug. When glycerol was omitted from crystals, the
WPD loop was entirely in the open conformation regardless of temperature, from cryogenic temper-
ature to near room temperature (data not shown). Our interpretation is that ordered glycerols in the
active site, which are evident from the electron density at all temperatures, make weak contacts with
the WPD loop’s closed conformation, and thus shift the protein’s energy landscape to a regime in
which the open vs. closed conformations are near enough to isoenergetic that temperature can
modulate their populations. This interpretation is strengthened by the fact that these glycerol
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molecules align well with a bound mimic of the pTyr substrate (PDB ID 1pty), which causes the loop
to close during the catalytic cycle.
For K197C, we used a similar refinement procedure, including many manual tweaks of alternative
conformations for protein and water atoms. For the 2-tethered K197C structure, we omitted 2 for
many rounds of refinement, allowing the electron density for the missing molecule to become
extremely convincing before we finally added it to the model. The distance between the sulfur atoms
in K197C and the ligand was restrained to 2.15 A˚ with a s of 0.1 A˚ for refinement.
For fragment-soaked datasets, we used the PanDDA approach (Pearce et al., 2017) in a few
stages. First, using PanDDA version 0.1, we ran pandda.analyse, and interpreted and modeled
events. Next, using the new PanDDA version 0.2, we ran pandda.analyse again. During this second
run, datasets which were events in the first run were excluded from background density calculation,
and datasets that had substantial map artifacts or very noisy/low-quality maps in the first run were
excluded entirely.
Some events for which we modeled bound fragments in the earlier PanDDA version 0.1 runs
were not detected as events in the final PanDDA version 0.2 run. In these cases, we manually created
event maps based on the 1-BDC background subtraction values from the earlier PanDDA runs. In
most cases, visual inspection confirmed that these early events likely correspond to bound
fragments.
Many PanDDA ‘events’ in the active site corresponded not to ligand binding, but rather to pro-
tein conformational changes of the WPD loop, P-loop, and Y46 loop that are caused by oxidation of
the catalytic Cys215, a natural PTP1B regulatory mechanism (van Montfort et al., 2003). Some
other active-site events were difficult to interpret, perhaps due to active-site dynamics or differences
in the appropriate background model for the open vs. closed state of the protein; future methodo-
logical improvements may clarify modeling in such cases.
We built a generic unbound-state model by interpreting both an average map for the highest-res-
olution bin and one of the best individual apo datasets. The WPD loop was modeled as open,
Tyr152 was modeled with two alternative sidechain conformations on the loop 11 backbone that is
compatible with the open WPD loop, and the N-terminus (start of a1) and C-terminus (end of a6,
since a7 was disordered) were fit as well as possible. Ordered waters were also manually positioned.
This generic unbound-state model was superposed onto each PanDDA input model in the correct
reference frame, then refined, to create an unbound-state model for each dataset.
For each fragment-bound state, we inspected the fragment binding site, plus the several interest-
ing regions of the protein mentioned above, in detail interactively. Waters were copied over from
the unbound-state model, then moved or deleted where they conflicted with the bound fragment
and/or the PanDDA event map. For a small number of planar fragments, several copies of the frag-
ment bind in a parallel stack bridging the 197 site and a symmetry-related copy of the WPD-loop
residue Phe182 via a crystal-lattice contact. Some areas such as Tyr152 were modeled with alterna-
tive conformations in the bound state only when they were well justified in the event map; otherwise
we generally adhered to the unbound-state model. The correct modeling choice for the termini was
uncertain in some cases.
To refine structures for the 110 datasets with one or more modeled fragments, first we created
restraints files for the ligands with eLBOW (Moriarty et al., 2009). For a small number of ligands, we
additionally used AceDRG (Long et al., 2017) and found that AceDRG generated more realistic
restraints. Next, the pandda.export method in PanDDA version 0.2 was used to create an ‘ensemble
structure’ containing both the unbound state (including alternative conformations) and the bound
state (including alternative conformations) in one multiconformer model. In pandda.export, the
parameter ‘options.prune_duplicates_rms = 0.2’ was used to merge alternative conformations that
were highly similar, and the parameter ‘duplicates.rmsd_cutoff = 0.4’ was used to restrain the coor-
dinates of somewhat similar alternative conformations to be identical. These parameter values were
chosen to effectively merge residues with very similar coordinates, while still allowing residues we
evaluated as having genuine alternative conformations to remain separate and unrestrained. The
resulting geometry restraint files from pandda.export are necessary to minimize overfitting or coor-
dinate drift during refinement of this model type.
For refinement of the ensembles representing multiconformer models of the apo and bound
states, we first refined each ensemble structure with phenix.refine to obtain water positions. The first
stage of PHENIX refinement was 10 macrocycles with no removal or addition of waters
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(‘ordered_solvent = False’) to let the existing waters relax into local minima. The second stage of
PHENIX refinement was another 10 macrocycles with automated removal and addition of waters
(‘ordered_solvent = True’) to remove waters that were unable to reach local minima and add waters
that were clearly missing. Adding and removing waters, when compared to only removing them,
generally had negligible effect on MolProbity scores, but improved Rwork and Rfree. During this first
PHENIX refinement stage to obtain water positions, occupancies were fixed to the original PanDDA
BDC value for the ground state and 1-BDC for the bound state; occupancy was distributed evenly
between substates when the ground state or the bound state had alternative conformations for
some residues. We observed coordinate drift and unstable B-factors for the protein with PHENIX
refinement. Therefore, we copied the water positions obtained from PHENIX into the initial ensem-
ble models, and refined with Refmac (Murshudov et al., 2011). To do so, we first set all B-factors to
40 A˚2, set bound-state occupancies to 2*(1-BDC) and unbound-state occupancies to 1–2*(1-BDC)
(with occupancy evenly distributed across alternative conformations within each state), and gener-
ated new restraints files that included the water molecules by running the PanDDA utility giant.mak-
e_restraints with the same RMSD parameter as with giant.merge_conformations: ‘duplicates.
rmsd_cutoff = 0.4’. Then, each ensemble model was refined with Refmac using giant.quick_refine
with the ligand CIF and custom giant.make_restraints restraint parameter files using the protocol
herein. First, each model was refined for the default 10 cycles, with the extra arguments to Refmac
‘MAKE HOUT Yes’, to preserve hydrogens, and ‘HOLD 0.001 100 100’ to restrain XYZ coordinates
but still allow for some geometry regularization and encourage B-factor and occupancy conver-
gence. Next, the output from that refinement was fed into a loop of Refmac refinement with the
default 10 cycles per run, and the ‘HOLD 0.0001 100 100’ argument, essentially fixing the XYZ coor-
dinates, while letting occupancies and B-factors refine. Our output was the result of the 4th round (1
round + 3 rounds) of refinement in Refmac. However, the occupancies refined with these refine-
ments did not converge to the correct occupancy (as seen by huge difference peaks describing the
ligand). We then refined these structures with PHENIX, fixing the XYZ coordinates and manually
scanning across possible occupancies while refining B-factors with the following settings: refinement.
refine.strategy = individual_adp, hydrogens.optimize_scattering_contribution = False, main.num-
ber_of_macro_cycles = 10, optimize_mask = True, optimize_adp_weight = True. While in principle
one could interpret the difference density to pick an optimal refined occupancy, no other statistics
calculated provided a clear choice of occupancy. We ultimately chose to deposit occupancies of the
bound state at 2.2 times the event map occupancy (1-BDC). This occupancy choice was motivated
by the trend previously found by Pearce et al. (2017). In cases where the total bound occupancy
was 50% or higher, the models were manually inspected, and a few dropped to low occupancies
that minimized difference features of the ligand. The resulting final ensemble structures of the
unbound state plus the fragment-bound state were converted from PDB to mmCIF format and
deposited in the PDB using the new multimodel submission procedure.
Visualization
Coot (Emsley et al., 2010) was instrumental to visualizing and interactively modeling all structures.
PyMOL (Schro¨dinger, 2016) was used for all molecular graphics after initial modeling. We frequently
used the volume rendering feature for low-contour electron density alongside the traditional mesh
for higher-contour electron density.
Synthesis of tethered compounds
Synthesis of 3-amino-2’,4’-difluoro-[1,1’-biphenyl] 4-ol
A solution of 2,4-difluorophenyl boronic acid (188 mg, 1 mmol, 1.0 equiv), 2-amino-4-bromophenol
(7.2 mg, 0.62 mmol, 1.2 equiv), Pd(PPh3)4 (57.8 mg, 0.05 mmol, 0.05 equiv), and Na2CO3 (318 mg, 3
mmol, three equiv) in THF (8 mL) was stirred at 90 ˚C overnight. The reaction was allowed to cool,
taken up in water, and then extracted 3x with EtoAC. Organic layers were combined, washed with
brine, dried over Na2SO4, concentrated in vacuo and purified using flash chromatography (MeOH/
DCM) to obtain 22.1 mg of product (10% yield). Calcd for C12H10F2NO (M+H
+): 222.07; Found
222.8.
Keedy et al. eLife 2018;7:e36307. DOI: https://doi.org/10.7554/eLife.36307 28 of 36
Research article Structural Biology and Molecular Biophysics
Synthesis of 2
To a mixture of 3-amino-2’,4’-difluoro-[1,1’-biphenyl] 4-ol (22.1 mg, 0.1 mmol, one equiv), dithiodi-
glycolic acid (9.1 mg, 0.05 mmol, 0.5 equiv), HOBtH2O (19.9 mg, 0.13 mmol, 1.3 equiv), and DIPEA
(0.226 mL, 1.3 mmol, 1.3 equiv) in THF (300 mL), EDCIHCl (25 mg, 0.13 mmol, 1.3 equiv) was added.
The reaction was stirred at room temperature overnight. To this was added a solution of bis[2-(N,N-
dimethylamino)ethyl]disulfide dihydrochloride (70.3 mg, 0.25 mmol, 2.5 equiv) and TCEP (2.5 mg,
0.01 mmol, 0.01 equiv) in THF/H2O (8:3, 275 mL). The reaction was stirred at room temperature over-
night. The reaction was taken up in EtoAC/H2O, and extracted three times with EtOAc. Organic
layers were combined, washed with brine, dried over Na2SO4, concentrated in vacuo and purified
using flash chromatography (DCM/MeOH) followed by preparative HPLC (C18 column (50  19 mm),
Methanol/Water–0.05% formic acid gradient: 10:90 to 100:0 over 12 min; 20 mL/min; 254 nm detec-
tion for 18 min.) to obtain 9.1 mg of 2 (23% yield). 1H NMR (400 MHz, Acetone-d6) d 9.55 (s, 1H),
8.17 (s, 1H), 8.06–8.04 (m, 1H), 7.54–7.45 (m, 1H), 7.22–7.19 (m, 1H), 7.12–7.00 (m, 3H), 3.94–3.78
(m, 2H), 3.15–2.99 (m, 4H), 2.54–2.52 (m, 6H). Calcd for C18H21F2N2O2S2 (M+H
+): 399.1; Found
398.93.
Tethering
We screened K197C against a previously synthesized library of 1600 disulfide fragments made avail-
able by the UCSF Small Molecule Discovery Center (SMDC) (Kathman et al., 2014;
Burlingame et al., 2011b).
For the screen, tethering reactions were performed using the following conditions: 1x tethering
buffer (25 mM Tris pH 7.5, 100 mM NaCl), with 500 nM of K197C, 1 mM b-mercaptoethanol, and
100 mM of fragment (0.2% DMSO), 1 hr at rt. Unless otherwise noted, tethering reactions for follow-
up experiments and activity assays were performed using the following conditions: 1x tethering
buffer, 1 mM of K197C, 0.1 mM b-mercaptoethanol, and 50 mM of fragment (2% DMSO), 1 hr at rt.
For DiFMUP assays 100 mM of fragment (0.2% DMSO) was used during tethering. For crystallogra-
phy, tethering reactions were performed using the following conditions: 1x tethering buffer, 0.76
mg/mL of K197C, 0.1 mM b-mercaptoethanol, 500 mM of TCS401, and 250 mM of fragment (2%
DMSO), 2 hr at rt. A total reaction size of 3.5 mL was used for preparation of crystallography sam-
ples. Following labeling, the reaction was dialyzed into crystallization buffer overnight to remove
TCS401 and unbound fragment. In all cases, the percent of tethering was measured using a Waters
Xevo G2-XS Mass Spectrometer, and calculated by comparing the relative peak heights of the
unmodified and modified protein. Tethering EC50 values were calculated using nonlinear fitting in
Prism 7 (Graphpad), n = 3.
Activity assays
For activity assays of WT* PTP1B vs. allosteric mutants (Figure 5—figure supplement 3), protein
was diluted to 269 nM (WT*) or 200 nM (mutants) in a variant of pNPP activity assay buffer (50 mM
HEPES pH 7, 100 mM NaCl, 1 mM EDTA, and 1 mM DTT). WT* assays were performed at 269 nM
protein and mutant assays were performed at 200 nM, so WT* data is normalized to 200 nM in both
panels in Figure 5—figure supplement 3. Enzyme activity assays were performed across 10 p-nitro-
phenyl phosphate (pNPP) concentrations obtained by serial two-fold dilutions starting from 20 mM.
A no-enzyme well was also assayed. Absorbance at 405 nm for each reaction was monitored every
30 s for 5 min using a Tecan Infinite M200 Pro. The rate (mAU/min) of each reaction was calculated
over the 5 min. Michaelis-Menten parameters were then calculated using Prism 7 (Graphpad). kcat
values were calculated using an pNPP extinction coefficient of 18,000 M 1 cm 1 and a path length
of 0.29 cm. These parameters for WT* PTP1B were similar to those reported previously for WT
(Choy et al., 2017); small discrepancies may be due in part to differences in the length of the pro-
tein construct being used.
For activity inhibition assays of WT* PTP1B with small-molecule fragments, 20 fragments were
chosen early in the iterative PanDDA analysis process (see ‘Structure modeling’). Protein was diluted
to 200 nM in a variant of pNPP activity assay buffer (50 mM HEPES pH 7, 100 mM NaCl, 1 mM
EDTA, 0.05% Tween-20, and 100 mM b-mercaptoethanol). Enzyme activity assays were performed
with 0.15 or 1 mM fragment in 2% DMSO (final) or with 2% DMSO without fragment as a control,
with 5 mM pNPP. A no-enzyme well was also assayed. Absorbance at 405 nm for each reaction was
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monitored every 30 s for 5 min. The rate (mAU/s) of each reaction was calculated over the 5 min.
These rates were compared with fragment vs. with DMSO.
For single-point assays of tethered K197C, completed tethering reactions (post 1 hr incubation)
were diluted to a final concentration of 200 nM K197C with a variant of pNPP activity assay buffer
(50 mM HEPES pH 7, 100 mM NaCl, 1 mM EDTA, 0.05% Tween-20, and 100 mM b-mercaptoetha-
nol) and pNPP (5 mM final). A no-enzyme well and a DMSO-only well were also assayed. Absorbance
at 405 for each reaction was monitored every 30 s for 5 min using a Tecan Infinite M200 Pro. Percent
inhibition was calculated using the following equation: 100(1- ((RateFragment-RateNo Enzyme)/(Rate-
DMSO-RateNo Enzyme))).
For 2 titration assays of tethered K197C and WT*, tethering reactions were performed at nine dif-
ferent concentrations of 2 obtained by serial three-fold dilutions starting at 50 mM. After 1 hr incuba-
tion, the reactions were diluted to a final concentration of 100 nM K197C and WT* with a variant of
pNPP activity assay buffer (50 mM HEPES pH 7, 100 mM NaCl, 1 mM EDTA, 0.05% Tween-20, and
100 mM b-mercaptoethanol), the same concentration of 2 as used during tethering, and pNPP (5
mM final). A no-enzyme well and a DMSO-only well were also assayed. Absorbance at 405 nm for
each reaction was monitored every 30 s for 5 min using a Tecan Infinite M200 Pro. The rate (mAU/s)
of each reaction was calculated over the 5 min. Percent inhibition was calculated using the following
equation: 100(1- ((RateFragment-RateNo Enzyme)/(RateDMSO-RateNo Enzyme))). Ki values were calculated
using nonlinear fitting in Prism 7 (Graphpad), n = 3.
For pNPP kinetics experiments with tethered complexes, completed K197C and WT* tethering
reactions (post 1 hr incubation) were diluted to a final concentration of 200 nM K197C and WT* with
a variant of pNPP activity assay buffer (50 mM HEPES pH 7, 100 mM NaCl, 1 mM EDTA, 0.05%
Tween-20, and 100 mM b-mercaptoethanol), 2 (50 mM), and 12 pNPP concentrations obtained by
serial two-fold dilutions starting from 20 mM. Absorbance at 405 nm for each reaction was moni-
tored every 30 s for 5 min using a Tecan Infinite M200 Pro. The rate (mAU/min) of each reaction was
calculated over the 5 min. Data was plotted and fit using Prism 7 (Graphpad), n = 3. Vmax and KM val-
ues were calculated using the Michaelis-Menten nonlinear fit in Prism 7 (Graphpad). All p-values and
significances were calculated using a FDR-Approach Multiple t-test in Prism 7 (Graphpad).
For DiFMUP inhibition experiments with tethered complexes, completed K197C and WT* tether-
ing reactions (post 1 hr incubation) were diluted to a final concentration of 2 nM K197C and WT*
with a variant of DiFMUP activity assay buffer (50 mM HEPES pH 7, 100 mM NaCl, 1 mM EDTA,
0.05% Tween-20), and 9.4 mM of DiFMUP. Fluorescence at 450 nm with 358 nm excitation for each
reaction was monitored every 30 s for 3 min using a Tecan Infinite M200 Pro. The rate (DF/min) of
each reaction was calculated over the 3 min. Percent inhibition was calculated using the following
equation: 100(1- ((RateFragment-RateNo Enzyme)/(RateDMSO-RateNo Enzyme))), n = 3.
For DiFMUP kinetics experiments with tethered complexes, completed K197C tethering reactions
(post 1 hr incubation) were diluted to a final concentration of 2 nM K197C with a variant of DiFMUP
activity assay buffer (50 mM HEPES pH 7, 100 mM NaCl, 1 mM EDTA, 0.05% Tween-20), and 11
DiFMUP concentrations obtained by serial two-fold dilutions starting from 300 mM. Fluorescence at
450 nm with 358 nm excitation for each reaction was monitored every 30 s for 3 min using a Tecan
Infinite M200 Pro. The rate (DF/min) of each reaction was calculated over the 3 min. Data was plot-
ted and fit using Prism 7 (Graphpad), n = 3. Vmax and KM values were calculated using the Michaelis-
Menten nonlinear fit in Prism 7 (Graphpad). All p-values and significances were calculated using a
FDR-Approach Multiple t-test in Prism 7 (Graphpad).
Data availability
Multiconformer models and structure factors for the multitemperature WT and WT* (6B90, 6B8E,
6B8T, 6B8X), BB3-bound (6B8Z), K197C apo (6BAI) and tethered (6B95) datasets have been depos-
ited in the Protein Data Bank (Berman et al., 2000).
We have made publicly available several files that document our PanDDA analysis of all WT* frag-
ment-soaked datasets. For each dataset, we provide a model of the unbound state, structure fac-
tors, an average map for the corresponding resolution bin, a PanDDA Z-map, and one or more
PanDDA event map(s) as applicable. For fragment-bound datasets, we also provide the refined
ground state model and the bound state model (before they were merged into an ensemble and
refined) as separate PDB files, along with PHENIX, Refmac, and ligand restraint files used in the
ensemble refinement. Additionally, we provide an overall PanDDA log file. These files are hosted at
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Zenodo at the following DOI: 10.5281/zenodo.1044103. Finally, using a new deposition procedure,
refined ensemble structures for the 110 WT* fragment-bound datasets have been deposited to the
PDB (5QDE, 5QDF, 5QDG, 5QDH, 5QDI, 5QDJ, 5QDK, 5QDL, 5QDM, 5QDN, 5QDO, 5QDP,
5QDQ, 5QDR, 5QDS, 5QDT, 5QDU, 5QDV, 5QDW, 5QDX, 5QDY, 5QDZ, 5QE0, 5QE1, 5QE2,
5QE3, 5QE4, 5QE5, 5QE6, 5QE7, 5QE8, 5QE9, 5QEA, 5QEB, 5QEC, 5QED, 5QEE, 5QEF, 5QEG,
5QEH, 5QEI, 5QEJ, 5QEK, 5QEL, 5QEM, 5QEN, 5QEO, 5QEP, 5QEQ, 5QER, 5QES, 5QET, 5QEU,
5QEV, 5QEW, 5QEX, 5QEY, 5QEZ, 5QF0, 5QF1, 5QF2, 5QF3, 5QF4, 5QF5, 5QF6, 5QF7, 5QF8,
5QF9, 5QFA, 5QFB, 5QFC, 5QFD, 5QFE, 5QFF, 5QFG, 5QFH, 5QFI, 5QFJ, 5QFK, 5QFL, 5QFM,
5QFN, 5QFO, 5QFP, 5QFQ, 5QFR, 5QFS, 5QFT, 5QFU, 5QFV, 5QFW, 5QFX, 5QFY, 5QFZ, 5QG0,
5QG1, 5QG2, 5QG3, 5QG4, 5QG5, 5QG6, 5QG7, 5QG8, 5QG9, 5QGA, 5QGB, 5QGC, 5QGD,
5QGE, 5QGF).
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